# EDGAR Filing Document

**Accession Number:** 0001482981
**File Stem:** 0001482981-25-000133
**Filing Date:** 2025-7
**Character Count:** 166836
**Document Hash:** dbc866b9e8810a32b76800c6247256af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001482981-25-000133.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001482981-25-000133

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 86

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250730

**DATE AS OF CHANGE**: 20250730

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vita Coco Company, Inc.
- **CENTRAL INDEX KEY:** 0001482981
- **STANDARD INDUSTRIAL CLASSIFICATION:** BEVERAGES [2080]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 113713156
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40950
- **FILM NUMBER:** 251164205

**BUSINESS ADDRESS:**
- **STREET 1:** 250 PARK AVENUE SOUTH
- **STREET 2:** SEVENTH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003
- **BUSINESS PHONE:** 212-206-0763

**MAIL ADDRESS:**
- **STREET 1:** 250 PARK AVENUE SOUTH
- **STREET 2:** SEVENTH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10003

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** All Market Inc.
- **DATE OF NAME CHANGE:** 20210824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** All Market, Inc.
- **DATE OF NAME CHANGE:** 20210824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vita Coco Company, Inc.
- **DATE OF NAME CHANGE:** 20210823

?xml version='1.0' encoding='ASCII'? coco-20250630

**<u>[**Table of Contents**](#i8e2f5d3941794fa0bd854c29eb8e4633_7)</u>**

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549**

____________________

**FORM 10-Q**

____________________

**(Mark One)** 

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended June 30, 2025**

**OR** 

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from** ____________ **to** ____________

**Commission File Number: 001-40950**

____________________

**The Vita Coco Company, Inc.**

**(Exact Name of Registrant as Specified in its Charter)** 

____________________

---

| | |
|:---|:---|
| **Delaware** | **11-3713156** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer<br>Identification No.)** |
| **250 Park Avenue South**<br>**Seventh Floor**<br>**New York, NY** | **10003** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(212) 206-0763**

**(Registrant's telephone number, including area code)** 

**N/A** 

**(Former name, former address and former fiscal year, if changed since last report)** 

____________________

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| **Common Stock, Par Value $0.01 Per Share** | **COCO** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | □ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| Emerging growth company | □ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes □ No ⌧

As of July 28, 2025, there were 56,822,981 shares of the registrant's common stock, par value $0.01 per share, outstanding.

------

**<u>[**Table of Contents**](#i8e2f5d3941794fa0bd854c29eb8e4633_7)</u>**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | **Page** |
| **<u>[PART I - FINANCIAL INFORMATION](#i8e2f5d3941794fa0bd854c29eb8e4633_13)</u>** | **<u>[PART I - FINANCIAL INFORMATION](#i8e2f5d3941794fa0bd854c29eb8e4633_13)</u>** | |
| [Item 1.](#i8e2f5d3941794fa0bd854c29eb8e4633_16) | <u>[Condensed Consolidated Financial Statements (unaudited)](#i8e2f5d3941794fa0bd854c29eb8e4633_16)</u> |  |
|  | <u>[Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024](#i8e2f5d3941794fa0bd854c29eb8e4633_19)</u> | [5](#i8e2f5d3941794fa0bd854c29eb8e4633_19) |
|  | <u>[Condensed Consolidated Statements of Operations & Other Comprehensive Income (Loss) for the three and six months ended June 30, 2025 and 2024](#i8e2f5d3941794fa0bd854c29eb8e4633_22)</u> | [6](#i8e2f5d3941794fa0bd854c29eb8e4633_22) |
|  | <u>[Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and 2024](#i8e2f5d3941794fa0bd854c29eb8e4633_25)</u> | [7](#i8e2f5d3941794fa0bd854c29eb8e4633_25) |
|  | <u>[Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024](#i8e2f5d3941794fa0bd854c29eb8e4633_28)</u> | [8](#i8e2f5d3941794fa0bd854c29eb8e4633_28) |
|  | <u>[Notes to Condensed Consolidated Financial Statements](#i8e2f5d3941794fa0bd854c29eb8e4633_31)</u> | [9](#i8e2f5d3941794fa0bd854c29eb8e4633_31) |
| [Item 2.](#i8e2f5d3941794fa0bd854c29eb8e4633_88) | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i8e2f5d3941794fa0bd854c29eb8e4633_88)</u> | [23](#i8e2f5d3941794fa0bd854c29eb8e4633_88) |
| [Item 3.](#i8e2f5d3941794fa0bd854c29eb8e4633_130) | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i8e2f5d3941794fa0bd854c29eb8e4633_130)</u> | [34](#i8e2f5d3941794fa0bd854c29eb8e4633_130) |
| [Item 4.](#i8e2f5d3941794fa0bd854c29eb8e4633_133) | <u>[Controls and Procedures](#i8e2f5d3941794fa0bd854c29eb8e4633_133)</u> | [35](#i8e2f5d3941794fa0bd854c29eb8e4633_133) |
| **<u>[PART II - OTHER INFORMATION](#i8e2f5d3941794fa0bd854c29eb8e4633_136)</u>** | **<u>[PART II - OTHER INFORMATION](#i8e2f5d3941794fa0bd854c29eb8e4633_136)</u>** |  |
| [Item 1.](#i8e2f5d3941794fa0bd854c29eb8e4633_139) | <u>[Legal Proceedings](#i8e2f5d3941794fa0bd854c29eb8e4633_139)</u> | [36](#i8e2f5d3941794fa0bd854c29eb8e4633_139) |
| [Item 1A.](#i8e2f5d3941794fa0bd854c29eb8e4633_142) | <u>[Risk Factors](#i8e2f5d3941794fa0bd854c29eb8e4633_142)</u> | [36](#i8e2f5d3941794fa0bd854c29eb8e4633_142) |
| [Item 2.](#i8e2f5d3941794fa0bd854c29eb8e4633_145) | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i8e2f5d3941794fa0bd854c29eb8e4633_145)</u> | [36](#i8e2f5d3941794fa0bd854c29eb8e4633_145) |
| [Item 3.](#i8e2f5d3941794fa0bd854c29eb8e4633_148) | <u>[Defaults Upon Senior Securities](#i8e2f5d3941794fa0bd854c29eb8e4633_148)</u> | [36](#i8e2f5d3941794fa0bd854c29eb8e4633_148) |
| [Item 4.](#i8e2f5d3941794fa0bd854c29eb8e4633_151) | <u>[Mine Safety Disclosures](#i8e2f5d3941794fa0bd854c29eb8e4633_151)</u> | [36](#i8e2f5d3941794fa0bd854c29eb8e4633_151) |
| [Item 5.](#i8e2f5d3941794fa0bd854c29eb8e4633_154) | <u>[Other Information](#i8e2f5d3941794fa0bd854c29eb8e4633_154)</u> | [36](#i8e2f5d3941794fa0bd854c29eb8e4633_154) |
| [Item 6.](#i8e2f5d3941794fa0bd854c29eb8e4633_160) | <u>[Exhibits](#i8e2f5d3941794fa0bd854c29eb8e4633_160)</u> | [38](#i8e2f5d3941794fa0bd854c29eb8e4633_160) |
| <u>[Signatures](#i8e2f5d3941794fa0bd854c29eb8e4633_163)</u> | <u>[Signatures](#i8e2f5d3941794fa0bd854c29eb8e4633_163)</u> | [40](#i8e2f5d3941794fa0bd854c29eb8e4633_163) |

---

------

**<u>[**Table of Contents**](#i8e2f5d3941794fa0bd854c29eb8e4633_7)</u>**

**FORWARD-LOOKING STATEMENTS** 

This Quarterly Report on Form 10-Q contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "forecasts," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements regarding our future results of operations and financial position, industry and business trends, equity compensation, business strategy, projected costs, plans, prospects, expectations, market growth, new products, supply chain predictions, and our objectives for future operations.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The forward-looking statements in this Quarterly Report on Form 10-Q are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

You should read this Quarterly Report on Form 10-Q and the documents that we reference herein and have filed as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this Quarterly Report on Form 10-Q, whether as a result of any new information, future events or otherwise.

As used in this Quarterly Report on Form 10-Q, unless otherwise stated or the context requires otherwise, the terms "Vita Coco," the "Company," "we," "us," and "our" refer to The Vita Coco Company, Inc. and its consolidated subsidiaries.

------

**<u>[**Table of Contents**](#i8e2f5d3941794fa0bd854c29eb8e4633_7)</u>**

**PART I—FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**THE VITA COCO COMPANY, INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)** 

**(Amounts in thousands, except share data)**

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $167042 | $164669 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance of $2,783 at June 30, 2025, and $2,255 at December 31, 2024 | 102551 | 63450 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 84110 | 83600 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supplier advances, current  | 1154 | 954 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative assets | 1174 | 1382 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 30713 | 27236 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 386744 | 341291 |
| Property and equipment, net | 3461 | 2351 |
| Goodwill | 7791 | 7791 |
| Supplier advances, long-term | 2130 | 2254 |
| Deferred tax assets, net | 6098 | 6100 |
| Right-of-use assets, net | 12222 | 385 |
| Other assets | 2631 | 2209 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $421077 | $362381 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $25834 | $30758 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 81399 | 65603 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes payable, current | 8 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative liabilities | 2802 | 6895 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 110043 | 103266 |
| Notes payable, long-term |  | 3 |
| Operating lease liability, long-term | 13996 |  |
| Other long-term liabilities | 99 | 295 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 124138 | 103564 |
| **Commitments and contingencies (See Note 7)** |  |  |
| **Stockholders' equity:** |  |  |
| Common stock, $0.01 par value; 500,000,000 shares authorized; 63,877,128 and 63,702,387 shares issued at June 30, 2025 and December 31, 2024, respectively 56,802,981 and 56,961,941 shares outstanding at June 30, 2025 and December 31, 2024, respectively | 639 | 637 |
| Additional paid-in capital | 178774 | 174077 |
| Retained earnings | 198484 | 156694 |
| Accumulated other comprehensive income (loss) | 826 | (860) |
| Treasury stock, 7,074,147 shares at cost as of June 30, 2025, and 6,740,446 shares at cost as of December 31, 2024.  | (81784) | (71731) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 296939 | 258817 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $421077 | $362381 |

---

*See accompanying notes to the condensed consolidated financial statements.*

------

**<u>[**Table of Contents**](#i8e2f5d3941794fa0bd854c29eb8e4633_7)</u>**

**THE VITA COCO COMPANY, INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS &** 

**OTHER COMPREHENSIVE INCOME (LOSS)** 

**(UNAUDITED)** 

**(Amounts in thousands, except for share and per share data)** 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net sales | $168759 | $144116 | $299680 | $255814 |
| Cost of goods sold | 107494 | 85379 | 190330 | 149900 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 61265 | 58737 | 109350 | 105914 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 36143 | 28756 | 64935 | 56974 |
| Income from operations | 25122 | 29981 | 44415 | 48940 |
| Other income (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain/(loss) on derivative instruments | 1067 | (5963) | 3884 | (8488) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency gain/(loss) | 482 | (136) | 1062 | (78) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 1500 | 1627 | 3018 | 3150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income |  |  | 155 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense) | 3049 | (4472) | 8119 | (5416) |
| Income before income taxes | 28171 | 25509 | 52534 | 43524 |
| Income tax expense | 5263 | 6416 | 10744 | 10193 |
| Net income | $22908 | $19093 | $41790 | $33331 |
| Other comprehensive income (loss) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 1191 | 33 | 1686 | $21 |
| Total comprehensive income attributable to The Vita Coco Company, Inc. | $24099 | $19126 | $43476 | $33352 |
| Net income per common share |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.40 | $0.34 | $0.73 | $0.59 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.38 | $0.32 | $0.70 | $0.57 |
| Weighted-average number of common shares outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 56795499 | 56705220 | 56894274 | 56647393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 59643348 | 59235211 | 59809039 | 58990921 |

---

*See accompanying notes to the condensed consolidated financial statements.* 

------

**<u>[**Table of Contents**](#i8e2f5d3941794fa0bd854c29eb8e4633_7)</u>**

**THE VITA COCO COMPANY, INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY** 

**(UNAUDITED)** 

**(Amounts in thousands, except for shares)**

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Common Stock<br>with Exit<br>Warrants** | **Common Stock<br>with Exit<br>Warrants** | **Total Common<br>Stock** | **Total Common<br>Stock** | **Additional<br>Paid-In** | **Retained<br>Earnings** | **Accumulated<br>Other<br>Comprehensive <br>Income / (Loss)** | **Treasury Stock** | **Treasury Stock** | **Total<br>Shareholders'<br>Equity<br>Attributable<br>to The Vita<br>Coco <br>Company, Inc.** |
| | **Shares** | **$ Amount** | **Shares** | **$ Amount** | **Shares** | **$ Amount** | **Capital** | **Retained<br>Earnings** | **Accumulated<br>Other<br>Comprehensive <br>Income / (Loss)** | **Shares** | **$ Amount** | **Total<br>Shareholders'<br>Equity<br>Attributable<br>to The Vita<br>Coco <br>Company, Inc.** |
| **Balance at December 31, 2023** | **55022348** | $**550** | **8113105** | $**81** | **63135453** | $**631** | $**161414** | $**100742** | $**(649)** | **6236200** | $**(59701)** | $**202437** |
| Net income |  |  |  |  |  |  |  | 14238 |  |  |  | 14238 |
| Purchase of treasury stock |  |  |  |  |  |  |  |  |  | 391544 | (9235) | (9235) |
| Stock-based compensation |  |  |  |  |  |  | 2109 |  |  |  |  | 2109 |
| Exercise of stock awards | 176284 | 2 |  |  | 176284 | 2 | 151 |  |  |  |  | 153 |
| Foreign currency translation adjustment |  |  |  |  |  |  |  |  | (12) |  |  | (12) |
| **Balance at March 31, 2024** | **55198632** | **552** | **8113105** | **81** | **63311737** | **633** | **163674** | **114980** | **(661)** | **6627744** | **(68936)** | **209690** |
| Net income |  |  |  |  |  |  |  | 19093 |  |  |  | 19093 |
| Stock-based compensation |  |  |  |  |  |  | 2399 |  |  |  |  | 2399 |
| Exercise of stock awards | 91376 | 1 |  |  | 91376 | 1 | 790 |  |  |  |  | 791 |
| Foreign currency translation adjustment |  |  |  |  |  |  |  |  | 33 |  |  | 33 |
| **Balance at June 30, 2024** | **55290008** | $**553** | **8113105** | $**81** | **63403113** | $**634** | $**166863** | $**134073** | $**(628)** | **6627744** | $**(68936)** | $**232006** |
| **Balance at December 31, 2024** | **55589282** | $**556** | **8113105** | $**81** | **63702387** | $**637** | $**174077** | $**156694** | $**(860)** | **6740446** | $**(71731)** | $**258817** |
| Net income |  |  |  |  |  |  |  | 18882 |  |  |  | 18882 |
| Purchase of treasury stock |  |  |  |  |  |  |  |  |  | 48973 | (1501) | (1501) |
| Stock-based compensation |  |  |  |  |  |  | 2186 |  |  |  |  | 2186 |
| Exercise of stock awards | 105332 | 1 |  |  | 105332 | 1 | (1022) |  |  |  |  | (1021) |
| Foreign currency translation adjustment |  |  |  |  |  |  |  |  | 495 |  |  | 495 |
| **Balance at March 31, 2025** | **55694614** | $**557** | **8113105** | $**81** | **63807719** | $**638** | $**175241** | $**175576** | $**(365)** | **6789419** | $**(73232)** | $**277858** |
| Net income |  |  |  |  |  |  |  | 22908 |  |  |  | 22908 |
| Purchase of treasury stock |  |  |  |  |  |  |  |  |  | 284728 | (8552) | (8552) |
| Stock-based compensation |  |  |  |  |  |  | 2962 |  |  |  |  | 2962 |
| Exercise of stock awards | 69409 | 1 |  |  | 69409 | 1 | 571 |  |  |  |  | 572 |
| Foreign currency translation adjustment |  |  |  |  |  |  |  |  | 1191 |  |  | 1191 |
| **Balance at June 30, 2025** | **55764023** | $**558** | **8113105** | $**81** | **63877128** | $**639** | $**178774** | $**198484** | $**826** | **7074147** | $**(81784)** | $**296939** |

---

*See accompanying notes to the condensed consolidated financial statements.*

------

**Table of Contents**

**THE VITA COCO COMPANY, INC. AND SUBSIDIARIES** 

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)** 

**(Amounts in thousands)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | $41790 | $33331 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments required to reconcile net income to cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 408 | 344 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance cost | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Gain)/loss on disposal of equipment |  | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bad debt expense | 608 | (204) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized (gain)/loss on derivative instruments | (3884) | 8488 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 5148 | 4508 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncash lease expense | 747 | 508 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (37758) | (28761) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 127 | 5254 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses, net supplier advances, and other assets | (1454) | (204) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses, and other liabilities | 6272 | 3375 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 12010 | 26652 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid for property and equipment | (1508) | (414) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (1508) | (414) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of stock awards | 977 | 681 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid on notes payable | (5) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid to acquire treasury stock | (10053) | (9235) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (9081) | (8562) |
| Effects of exchange rate changes on cash and cash equivalents | 961 | (106) |
| Net increase in cash and cash equivalents | 2382 | 17570 |
| Cash, cash equivalents and restricted cash at beginning of the period (1) | 165933 | 132867 |
| Cash, cash equivalents and restricted cash at end of the period (1) | $168315 | $150437 |

---

<sup>1</sup>Includes $1,273 and $334 of restricted cash as of June 30, 2025 and 2024, respectively, reported in other current assets on the condensed consolidated balance sheet.

*See accompanying notes to the condensed consolidated financial statements.*

------

**Table of Contents**

**THE VITA COCO COMPANY, INC. AND SUBSIDIARIES** 

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)** 

**(Amounts in thousands, except share and per share amounts)**

**1. NATURE OF BUSINESS AND BASIS OF PRESENTATION**

The Vita Coco Company, Inc. and subsidiaries (the "Company") develops, markets, and distributes various coconut water products under the brand name *Vita Coco* and for retailers' own brands, predominantly in the United States ("U.S."). Other products include coconut milk, coconut oil, water (under the brand name *Ever & Ever*), protein infused fitness drinks (under the brand name *PWR LIFT*), and other revenue transactions (e.g., bulk product sales). The Company completed an initial public offering (the "IPO") of its Common Stock in October 2021.

We are a public benefit corporation under Section 362 of the Delaware General Corporation Law. As a public benefit corporation, our Board of Directors (the "Board") is required by the Delaware General Corporation Law to manage or direct our business and affairs in a manner that balances the pecuniary interests of our stockholders, the best interests of those materially affected by our conduct and the specific public benefits identified in our certificate of incorporation.

The Company has ten wholly-owned subsidiaries, including four wholly-owned Asian subsidiaries established between fiscal 2012 and 2015, four North American subsidiaries established between 2012 and 2018, All Market Europe, Ltd. ("AME") in the United Kingdom established in 2009, and one subsidiary in Germany established during 2024. Through one of its subsidiaries, the Company has a 60% joint venture interest in a company, Coco Ventures Limited, which provides for the development, marketing, distribution and branding of coconut water-based products under the Vita Coco brand in China. See Note 16, *Joint Venture*, for further details.

*Unaudited interim financial information* 

The Company's condensed consolidated interim financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and Article 10 of Regulation S-X. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of the Company's financial information for the interim period presented. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any other interim period or for any other future year. The condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the fiscal year ended December 31, 2024.

During the six months ended June 30, 2025, there were no significant changes to the Company's significant accounting policies as described in the Company's audited consolidated financial statements as of and for the year ended December 31, 2024.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES** 

*Basis of Presentation* 

The accompanying condensed consolidated financial statements are presented in accordance with U.S. GAAP.

*Principles of Consolidation* 

The condensed consolidated financial statements include all the accounts of the wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

*Use of Estimates* 

Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Management must apply significant judgment in this process. In addition, other factors

------

**Table of Contents**

may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. Additionally, uncertainty in the macroeconomic environment resulting from current geopolitical and economic instability (including the effects of current wars and other international conflicts, as well as recently imposed tariffs) and the high interest rate and inflationary cost environment make estimates and assumptions difficult to calculate with precision. The estimation process often may yield a range of reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. The most significant estimates in the condensed consolidated financial statements relate to share-based compensation, assessing long-lived assets for impairment, estimating the net realizable value of inventories, determining the accounts receivables reserve, assessing goodwill for impairment, determining the value of trade promotions, and assessing the realizability of deferred income taxes. Actual results could differ from those estimates.

*Concentration of Credit Risk* 

The Company's cash and accounts receivable are subject to concentrations of credit risk. The Company's cash balances are primarily on deposit with banks in the U.S. which are guaranteed by the Federal Deposit Insurance Corporation ("FDIC") up to $250. At times, such cash may be in excess of the FDIC insurance limit. To minimize the risk, the Company's policy is to maintain cash balances with high quality institutions, which may include banks, financial institutions and investment firms, and invest daily or reserve operating cash in money market funds, government securities, bank obligations, municipal securities or other investment vehicles with short-term maturities.

Substantially all of the Company's customers are either wholesalers or retailers of beverages. A material default in payment, a material reduction in purchases from these or any large customers, or the loss of a large customer or customer groups could have a material adverse impact on the Company's financial condition, results of operations and liquidity. The Company is exposed to concentration of credit risk from its major customers, for which two customers in aggregate represented 45% and 49% of total net sales for the six months ended June 30, 2025 and 2024, respectively. In addition, the two customers in aggregate also accounted for 44% and 30% of total accounts receivable as of June 30, 2025 and December 31, 2024, respectively. The Company has not experienced credit issues with these customers. Refer to Note 7, *Commitments and Contingencies* regarding additional information on the Company's major customers.

*Recently Adopted Accounting Pronouncements* 

*Segment Reporting* 

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments' significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in Accounting Standards Codification ("ASC") - Topic 280 on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted the standard for the year ended December 31, 2024. The adoption of the standard did not have a material impact on the Company's condensed consolidated statements of operations and disclosures.

*Recently Issued Accounting Pronouncements* 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which requires expenses in the consolidated statement of operations to be disaggregated into functional categories and separate significant individual expense items that are material to the understanding of the financial statements. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026. In January 2025, the FASB issued ASU 2025-01, which clarified the adoption date to include interim periods with annual reporting periods after December 31, 2027. The Company is currently evaluating the impact of adopting ASU 2024-03.

*Income Taxes*

In December 2023, the FASB issued ASU 2023-09, Income Taxes ("Topic 740"): Improvements to Income Tax Disclosures ("ASU 2023-09"), which requires public entities, on an annual basis, to provide disclosure of specific

------

**Table of Contents**

categories in the effective tax rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting standard on its consolidated financial statements.

**3. REVENUE RECOGNITION**

Revenues are accounted for in accordance with ASC Topic 606, Revenue Recognition ("ASC 606"). The Company disaggregates revenue into the following product categories:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Vita Coco Coconut Water***—This product category consists of all branded coconut water product offerings under the *Vita Coco* labels, where the majority ingredient is coconut water. The Company determined that the sale of the products represents a distinct performance obligation as customers can benefit from purchasing the products on their own or together with other resources that are readily available to the customers. For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Private Label***—This product category consists of all private label product offerings, which includes coconut water and oil. The Company determined the production and distribution of private label products represents a distinct performance obligation. Since there is no alternative use for these products and the Company has the right to payment for performance completed to date, the Company recognizes the revenue for the production of these private label products over time as the production for open purchase orders occurs, which may be prior to any shipment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Other***—This product category consists of all other products, which includes *Vita Coco* product extensions beyond coconut water, consisting of coconut milk products, including *Vita Coco* Treats; *Ever & Ever* and *PWR LIFT* product offerings; *Vita Coco* coconut oil sold internationally; and other revenue transactions (e.g., bulk product sales). For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

The Company excludes from revenues all taxes assessed by a governmental authority that are imposed on the sale of its products and collected from customers.

The Company provides trade promotions and sales discounts to its customers and distributors. Since these sales promotions and sales discounts do not meet the criteria for a distinct good or service, they are primarily accounted for as a reduction of revenue and include payments to customers and distributors for performing activities on our behalf, such as payments for in-store displays, payments to gain distribution of new products, payments for shelf space and discounts to promote lower retail prices. These condensed consolidated financial statements include accruals for these promotions and discounts. The accruals are made for invoices that have not yet been received as of the end of the reporting period and are recorded as a reduction of sales, and are based on contract terms and our historical experience with similar programs and require management judgment with respect to estimating customer and consumer participation and performance levels.

*Disaggregation of Revenue* 

The following table disaggregates net revenue by product type and reportable segment:

------

**Table of Contents**

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** |
| | **Americas** | **International** | **Consolidated** |
| Vita Coco Coconut Water | $120450 | $19882 | $140332 |
| Private Label | 14685 | 6222 | 20907 |
| Other | 6826 | 694 | 7520 |
| Total | $141961 | $26798 | $168759 |
|  | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** |
|  | **Americas** | **International** | **Consolidated** |
| Vita Coco Coconut Water | $98494 | $13952 | $112446 |
| Private Label | 23135 | 4816 | 27951 |
| Other | 2873 | 846 | 3719 |
| Total | $124502 | $19614 | $144116 |
|  | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** | **Six Months Ended June 30, 2025** |
|  | **Americas** | **International** | **Consolidated** |
| Vita Coco Coconut Water | $206568 | $33059 | $239627 |
| Private Label | 35882 | 10981 | 46863 |
| Other | 12111 | 1079 | 13190 |
| Total | $254561 | $45119 | $299680 |
|  | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** | **Six Months Ended June 30, 2024** |
|  | **Americas** | **International** | **Consolidated** |
| Vita Coco Coconut Water | $168016 | $23617 | $191633 |
| Private Label | 47408 | 9968 | 57376 |
| Other | 5169 | 1636 | 6805 |
| Total | $220593 | $35221 | $255814 |

---

**4. INVENTORY** 

Inventory consists of the following:

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| Raw materials and packaging | $4737 | $3536 |
| Finished goods | 79373 | 80064 |
| Inventory | $84110 | $83600 |

---

**5. GOODWILL** 

Goodwill consists of the following:

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| Goodwill | $7791 | $7791 |

---

All of the Company's goodwill is associated with a June 2018 acquisition. The goodwill is allocated to the Americas reporting unit and is tax deductible. The Company has not recognized any impairment since the acquisition in accordance with ASC Topic 350 - Intangibles, Goodwill & Other.

------

**Table of Contents**

**6. DEBT** 

The table below details the outstanding balances on the Company's debt as of June 30, 2025 and December 31, 2024:

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| **Notes payable** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vehicle loans | 8 | 13 |
|  | $8 | $13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Current* | 8 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Non-current* | $— | 3 |

---

***2020 Credit Facility***

In May 2020, the Company entered into a five-year credit facility with Wells Fargo Bank, National Association consisting of a revolving line of credit, which provides for committed borrowings of $60,000 (the "2020 Credit Facility"). On February 14, 2025, the 2020 Credit Facility was amended, extending the maturity date five years to February 13, 2030. In connection with the amendment, the Company capitalized $90 of deferred financing costs, which are being amortized over the term of the facility. As of June 30, 2025, the unamortized deferred financing fees related to the revolver totaled $83 and are included in Other assets on the Company's condensed consolidated balance sheet.

Starting in December 2022, borrowings on the 2020 Credit Facility bear interest at rates based on either: 1) a fluctuating rate per annum determined to be the sum of Daily Simple Secured Overnight Financing Rate ("SOFR") plus a spread defined in the credit agreement (the "Spread"); or 2) a fixed rate per annum determined to be the sum of the Term SOFR plus the Spread. The Spread ranges from 1.00% to 1.75%, which is based on the Company's leverage ratio (as defined in the credit agreement) for the immediately preceding fiscal quarter as defined in the credit agreement. In addition, the Company was subject to unused commitment fees ranging from 0.10% and 0.20% on the unused amount of the line of credit in the year ended December 31, 2024, with the rate based on the Company's leverage ratio (as defined in the 2020 Credit Facility). Starting February 14, 2025, the unused commitment fees range from 0.13% and 0.23% on the unused amount of the line of credit, with the rate being based on the Company's leverage ratio (as defined in the 2020 Credit Facility).

As of June 30, 2025 and December 31, 2024, the Company had no outstanding balance and $60,000 undrawn and available under its amended 2020 Credit Facility. The Company incurred no interest expense for the 2020 Credit Facility for the six months ended June 30, 2025 and June 30, 2024, respectively. The unused commitment fee for the 2020 Credit Facility amounted to $19 and $15 for the three months ended June 30, 2025 and June 30, 2024, respectively. The unused commitment fee for the 2020 Credit Facility amounted to $36 and $30 for the six months ended June 30, 2025 and June 30, 2024, respectively.

The 2020 Credit Facility is collateralized by substantially all of the Company's assets.

The 2020 Credit Facility contains certain affirmative and negative covenants that, among other things, limit the Company's ability to, subject to various exceptions and qualifications: (i) incur liens; (ii) incur additional debt; (iii) sell, transfer or dispose of assets; (iv) merge with or acquire other companies; (v) make loans, advances or guarantees; (vi) make investments; (vii) make dividends and distributions on, or repurchases of, equity; and (viii) enter into certain transactions with affiliates. The 2020 Credit Facility also requires the Company to maintain certain financial covenants including a maximum leverage ratio, a minimum fixed charge coverage ratio, and a minimum asset coverage ratio. As of June 30, 2025, the Company was in compliance with all financial covenants.

*Vehicle Loans* 

We periodically enter into vehicle loans. Interest rates on these vehicle loans range from 4.56% to 5.68%. The outstanding balance on the vehicle loans as of June 30, 2025 was less than $100.

------

**Table of Contents**

**7. COMMITMENTS AND CONTINGENCIES** 

*Contingencies:* 

***Litigation***—The Company may engage in various litigation matters in the ordinary course of business. The Company intends to vigorously defend itself in such matters, based upon the advice of legal counsel, and is of the opinion that the resolution of these matters will not have a material effect on the condensed consolidated financial statements. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also discloses when it is reasonably possible that a material loss may be incurred. As of June 30, 2025 and December 31, 2024, the Company has not recorded any liabilities relating to such legal matters.

***Business Risk***—The Company imports finished goods predominantly from manufacturers located in South American and Southeast Asian countries. The Company may be subject to certain business risks due to potential instability in these regions.

***Major Customers***—The Company's customers that accounted for 10% or more of total net sales and total accounts receivable were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Net sales** | **Net sales** | **Accounts receivable** | **Accounts receivable** |
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **June 30,** | **December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| Customer A | 20% | 27% | 23% | 13% |
| Customer B | 25% | 22% | 21% | 17% |

---

Net sales include branded and private label products. One of the customers acquired less than 5% ownership in the Company upon consummation of the IPO. As discussed in Note 11, *Stock-Based Compensation*, the same customer also was granted 200,000 restricted stock awards at the time of the IPO, of which 100,000 vested on March 31, 2023 and 100,000 vested on March 31, 2024. The customer monetized its investment in the Company during the first quarter of 2025.

***Major Suppliers***—The Company's suppliers that accounted for 10% or more of the Company's purchases were as follows:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| Supplier A | 15% | 22% |
| Supplier B | 14% | 14% |
| Supplier C | 13% | 8% |

---

**8. DERIVATIVE INSTRUMENTS** 

The Company accounts for derivative instruments in accordance with the ASC Topic 815, Derivatives and Hedging ("ASC 815"). These principles require that all derivative instruments be recognized at fair value on each balance sheet date unless they qualify for a scope exclusion as a normal purchase or sales transaction, which is accounted for under the accrual method of accounting. In addition, these principles permit derivative instruments that qualify for hedge accounting to reflect the changes in the fair value of the derivative instruments through earnings or stockholders' equity as other comprehensive income on a net basis until the hedged item is settled and recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative instrument's change in fair value is immediately recognized in earnings. As of June 30, 2025 and December 31, 2024, the Company did not have any derivative instruments that it had designated as fair value or cash flow hedges.

The Company is subject to the following currency risks:

***Inventory Purchases from Brazilian, Malaysian and Thai Manufacturers***—In order to mitigate the currency risk on inventory purchases from its Brazilian, Malaysian and Thai manufacturers, which are settled in Brazilian real ("BRL"), Malaysian ringgit ("MYR") and Thai baht ("THB"), the Company's subsidiary, All Market Singapore Pte. Ltd. ("AMS"), enters into a series of forward currency swaps to buy BRL, MYR and THB.

------

**Table of Contents**

***Intercompany Transactions Between AME and AMS***—In order to mitigate the currency risk on intercompany transactions between AME and AMS, AMS enters into foreign currency swaps to sell British pounds ("GBP").

***Intercompany Transactions with Canadian Customer and Vendors***—In order to mitigate the currency risk on transactions with Canadian customer and vendors, the Company enters into foreign currency swaps to sell Canadian dollars ("CAD").

The notional amount and fair value of all outstanding derivative instruments in the condensed consolidated balance sheets consist of the following at:

---

| | | | |
|:---|:---|:---|:---|
| **June 30, 2025** | **June 30, 2025** | **June 30, 2025** | **June 30, 2025** |
| Derivatives not designated as<br>hedging instruments under<br>ASC 815-20 | Notional<br>Amount | Fair<br>Value | Balance Sheet Location |
| **Assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange contracts |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive BRL/sell USD | $27743 | $603 | Derivative assets |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive THB/sell USD | 17352 | 476 | Derivative assets |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive Eur/pay USD | 1516 | 95 | Derivative assets |
| **Liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange contracts |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/pay GBP | $22590 | $(1787) | Derivative liabilities |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/pay EUR | 9245 | (730) | Derivative liabilities |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/sell THB | 4582 | (219) | Derivative liabilities |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/pay CAD | 6211 | (66) | Derivative liabilities |

---

---

| | | | |
|:---|:---|:---|:---|
| **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| Derivatives not designated as<br>hedging instruments under<br>ASC 815-20 | Notional<br>Amount | Fair<br>Value | Balance Sheet Location |
| **Assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange contracts |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/pay EUR | $9060 | $458 | Derivative assets |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/pay GBP | 26303 | 464 | Derivative assets |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive USD/pay CAD | 8486 | 460 | Derivative assets |
| **Liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency exchange contracts |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive THB/sell USD | $28066 | $(623) | Derivative liabilities |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receive BRL/sell USD | 35443 | (6272) | Derivative liabilities |

---

&nbsp;&nbsp;&nbsp;&nbsp;

The amount and location of realized and unrealized gains and losses of the derivative instruments in the condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024 are as follows:

------

**Table of Contents**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
| | **2025** | **2024** |
| **Unrealized gain/(loss) on derivative instruments** | $1067 | $(5963) |
| **Foreign currency gain/(loss)** | $(1289) | $188 |
|  | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** |
| **Unrealized gain/(loss) on derivative instruments** | $3884 | $(8488) |
| **Foreign currency gain/(loss)** | $(2621) | $795 |

---

The Company applies recurring fair value measurements to its derivative instruments in accordance with ASC Topic 820, Fair Value Measurements ("ASC 820"). In determining fair value, the Company used a market approach and incorporates the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated or generally unobservable internally developed inputs.

***9.* FAIR VALUE MEASUREMENTS** 

ASC 820 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observability of the inputs used in valuation techniques, the Company's assets and liabilities are classified as follows:

***Level 1***—Quoted market prices in active markets for identical assets or liabilities.

***Level 2***—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted market prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

***Level 3***—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes internally developed models and methodologies utilizing significant unobservable inputs.

***Forward Currency Swap Contracts***—See Note 8, *Derivative Instruments*, for a description of these contracts. The Company's valuation methodology for forward currency swap contracts is based upon third-party institution data.

The Company's fair value hierarchy for those assets (liabilities) measured at fair value on a recurring basis at June 30, 2025 and December 31, 2024, is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| | | **Forward Currency<br>Swaps/Contracts** | | |
| **June 30, 2025** | $— | $(1628) | $— | $(1628) |
| **December 31, 2024** | $— | $(5513) | $— | $(5513) |

---

There were no transfers between any levels of the fair value hierarchy for any of the Company's fair value measurements.

**10. STOCKHOLDERS' EQUITY** 

***Common and Treasury Stock***—Each share of Common Stock entitles its holder to one vote on matters required to be voted on by the stockholders of the Company and to receive dividends, when and if declared by the Company's Board.

------

**Table of Contents**

As of June 30, 2025 and December 31, 2024, the Company held 7,074,147 and 6,740,446 shares, respectively, in treasury stock. As of June 30, 2025 and December 31, 2024, the Company had 2,803,388 and 3,254,762 shares, respectively, of Common Stock available for issuance upon the conversion of outstanding equity awards under the 2021 Incentive Award Plan ("2021 Plan").

On October 30, 2023, the Company's Board approved a share repurchase program (the "Repurchase Program") authorizing the Company to repurchase up to $40,000 of Common Stock. On April 28, 2025, the Company's Board approved an additional $25,000 to the Repurchase Program, authorizing the Company to repurchase up to a total of $65,000 of the Company's Common Stock. There were no other changes made to the terms of the Repurchase Program. Shares of Common Stock may be repurchased under the Repurchase Program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs. To the extent not retired, shares of Common Stock repurchased under the Repurchase Program will be placed in the Company's treasury shares. The extent to which the Company repurchases shares of Common Stock, and the timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company. The Repurchase Program has no time limits and may be suspended or discontinued at any time. The Company repurchased 284,728 shares during the three months ended June 30, 2025 at a cost of $8,552. The Company repurchased 333,701 shares under the Repurchase Program at a cost of $10,053 during the six months ended June 30, 2025. The Company repurchased 504,246 shares under the Repurchase Program at a cost of $12,030 during the year ended December 31, 2024. As of June 30, 2025, the Company had $42,143 remaining under the Repurchase Program.

**11. STOCK-BASED COMPENSATION**

The stockholders of the Company approved the adoption of the Company's 2014 Stock Option and Restricted Stock Plan (the "2014 Plan"). The 2014 Plan allowed for a maximum of 8% of the sum of the Available Equity defined as the sum of: (i) the total then outstanding shares of common shares; and (ii) all available stock options (i.e., granted and outstanding stock options and stock options not yet granted). Under the terms of the 2014 Plan, the Company may grant employees, directors and consultants stock options and restricted stock awards and has the authority to establish the specific terms of each award, including exercise price, expiration and vesting. The 2014 Plan includes only outstanding stock options, all of which were granted before the Company's IPO. Generally, stock options issued pursuant to the 2014 Plan contain exercise prices no less than the fair value of Common Stock on the date of grant and have a ten-year contractual term.

In October 2021, the stockholders of the Company approved the adoption of the 2021 Incentive Award Plan ("2021 Plan"), which became effective after the closing of the IPO. On and after closing of the offering and the effectiveness of the 2021 Plan, no further grants have been made under the 2014 Plan. The maximum number of shares of our Common Stock available for issuance under the 2021 Plan is equal to the sum of: (i) 3,431,312 shares of our Common Stock; and (ii) an annual increase on the first day of each year beginning in 2022 and ending in and including 2031, equal to the lesser of (A) two percent (2%) of the outstanding shares of our Common Stock on the last day of the immediately preceding fiscal year; and (B) such lesser amount as determined by our Board; provided, however, no more than 3,431,312 shares may be issued upon the exercise of incentive stock options ("ISOs"). The 2021 Plan provides for the grant of stock options, including ISOs and nonqualified stock options ("NSOs"), dividend equivalents, stock payments, service-based restricted stock units ("RSUs"), performance-based restricted stock units ("PSUs"), other incentive awards, stock appreciation rights ("SARs"), and cash awards. For the year beginning January 1, 2025, the Board elected not to increase the shares available for the 2021 Plan. As of June 30, 2025, only stock options, RSUs, and PSUs have been granted under the 2021 Plan.

For the three and six months ended June 30, 2025 and 2024, the Company recorded stock compensation costs totaling:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended**<br> **June 30,** | **Three months ended**<br> **June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Reduction in revenue <sup>(1)</sup> | $— | $— | $— | $151 |
| Selling, general & administrative expenses | $2962 | $2399 | $5148 | $4357 |
| Total stock compensation expense | $2962 | $2399 | $5148 | $4508 |

---

<sup>(1)</sup> The cost recognized as a reduction in revenue is related to the RSUs previously granted to a major customer based on guidance in ASC 606 as stock-based sales incentive. These awards are shares of restricted Common Stock valued at $3,000

------

**Table of Contents**

granted at the time of the IPO to an entity affiliated with a significant customer, at a price per share granted at the IPO of $15.00, or 200,000 restricted shares, in connection with an amendment to extend the distributor agreement term to June 10, 2026. Since the distribution agreement had not been terminated by either party for cause as of March 31, 2023, 50% of the shares were released on March 31, 2023. The remaining 50% were released on March 31, 2024.

*Option Awards with Service-based Vesting Conditions*

Most of the stock option awards granted under the 2014 Plan and 2021 Plan vest based on continuous service. The options awarded to the employees have differing vesting schedules as specified in each grant agreement. The following table summarizes the service-based stock option activity during the six months ended June 30, 2025:

---

| | |
|:---|:---|
| | **Number of <br>Stock <br>Options** |
| Outstanding—December 31, 2024 | 3,054,060 |
| Granted | 201,100 |
| Exercised | 93,831 |
| Forfeited or expired | 21,828 |
| Outstanding—June 30, 2025 | 3,139,501 |
| Exercisable—June 30, 2025 | 2,373,334 |

---

The fair value of the service-based stock options granted in 2025 and 2024 pursuant to the 2021 Plan was estimated on a grant or on a modification date using the Black-Scholes option-pricing model. The weighted average assumptions used in the Black-Scholes option-pricing model were as follows:

---

| | | |
|:---|:---|:---|
| | **2025** | **2024** |
| Weighted average expected term | 6.25 years | 6.25 years |
| Weighted average expected volatility | 31% | 32% |
| Weighted average risk-free interest rate | 4.10% | 4.00% |
| Weighted average expected dividend yield | 0% | 0% |

---

*Option Awards with Performance and Market-based Vesting Conditions* 

The Company also has outstanding stock option awards containing performance-based vesting conditions, subject to achievement of various performance goals by a future period, such as revenue and Adjusted EBITDA targets. During the six months ended June 30, 2025, there was no activity related to the existing stock options with performance-based vesting conditions and no grants of stock option awards with performance-based vesting conditions.

*Service-based and Performance-based Restricted Stock*

RSUs were granted under the 2021 Plan and primarily vest based on continuous service. The RSUs with service-based vesting conditions awarded to the employees have differing vesting schedules as specified in each grant agreement. The RSUs granted to non-employee directors vest in full on the earlier of: (i) the day immediately preceding the date of the first Annual Shareholders Meeting following the date of grant; or (ii) the first anniversary of the date of grant. During the six months ended June 30, 2025 and June 30, 2024, the Company also granted PSUs, which are subject to achievement of

------

**Table of Contents**

various performance goals in the future, specifically net sales growth and Adjusted EBITDA targets. The following table summarizes the RSU and PSU activity for the six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
| | **Number of RSU Awards** | **Number of PSU Awards** |
| Non-vested - December 31, 2024 | 634803 | 74579 |
| Granted | 206506 | 71140 |
| Vested | 122983 |  |
| Forfeited/Cancelled | 17666 | 1528 |
| Non-vested - June 30, 2025 | 700660 | 144191 |

---

**12. INCOME TAXES**

For the three months ended June 30, 2025 and 2024, the Company recorded income tax expense of $5,263 and $6,416, respectively, in its condensed consolidated statements of operations. For the six months ended June 30, 2025 and 2024, the Company recorded income tax expense of $10,744 and $10,193, respectively, in its condensed consolidated statements of operations.

In assessing the recoverability of its deferred tax assets, the Company continually evaluates all available positive and negative evidence to assess the amount of deferred tax assets for which it is more likely than not to realize a benefit. For any deferred tax asset in excess of the amount for which it is more likely than not that the Company will realize a benefit, the Company establishes a valuation allowance.

As of June 30, 2025 and December 31, 2024, the Company recorded a liability of $88 and $106, respectively, for income tax uncertainties recorded in the Company's condensed consolidated balance sheet and consolidated balance sheet, respectively. The Company's policy is to record interest and penalties related to income taxes as part of its income tax provision. The Company does not expect its uncertain tax positions to change significantly over the next twelve months. The Company recognized interest and penalties related to income tax uncertainties of $6 and $0, respectively, in its condensed consolidated statement of operations for the six months ended June 30, 2025 and 2024. The Company is subject to income tax examinations by the Internal Revenue Service ("IRS") and various state and local jurisdictions for the open tax years between December 31, 2019 and December 31, 2023.

On July 4, 2025, the United States enacted tax reform legislation through the passage of H.R.1, One Big Beautiful Bill Act, which changes existing U.S. tax laws, including extending or making permanent certain provisions of the 2017 Tax Cuts and Jobs Act, and repealing certain clean energy initiatives, in addition to other changes. The Company continues to evaluate the impact that the new legislation will have on the consolidated financial statements but does not anticipate a significant impact to deferred tax assets and liabilities or to income taxes payable in the period of enactment.

------

**Table of Contents**

**13. EARNINGS PER SHARE** 

Basic and diluted earnings per share were calculated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended**<br> **June 30,** | **Three months ended**<br> **June 30,** | **Six months ended**<br> **June 30,** | **Six months ended**<br> **June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| <u>Numerator:</u> |  |  |  |  |
| Net income | $22908 | $19093 | $41790 | $33331 |
| <u>Denominator:</u> |  |  |  |  |
| Weighted-average number of common shares used in earnings per share—basic | 56795499 | 56705220 | 56894274 | 56647393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of conversion of stock options | 2847849 | 2529991 | 2914765 | 2343528 |
| Weighted-average number of common shares used in earnings per share—diluted | 59643348 | 59235211 | 59809039 | 58990921 |
| Earnings per share—basic | $0.40 | $0.34 | $0.73 | $0.59 |
| Earnings per share—diluted | $0.38 | $0.32 | $0.70 | $0.57 |

---

The following potentially dilutive securities, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average number of common shares outstanding, as they would be anti-dilutive:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended**<br>**June 30,** | **Three months ended**<br>**June 30,** | **Six months ended**<br>**June 30,** | **Six months ended**<br>**June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Options to purchase Common Stock and RSUs | 381471 | 207168 | 275595 | 254490 |

---

**14. SEGMENT REPORTING**

The Company has two operating and reportable segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Americas—The Americas segment is comprised primarily of the U.S. and Canada, and derives its revenues from the marketing and distribution of various coconut water and non-coconut water products (e.g., coconut oil and milk). The Company's aluminum bottle canned water (*Ever & Ever*) and protein infused fitness drink (*PWR LIFT*) are marketed only in the Americas segment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• International—The International segment is comprised primarily of Europe, the Middle East, and Asia Pacific. Asia Pacific includes the Company's procurement arm and derives its revenues from the marketing and distribution of various coconut water and non-coconut water products, including product that is shipped directly to customers outside of Asia Pacific regions.

All intercompany transactions between the segments have been eliminated.

The Company's CEO is the chief operating decision maker ("CODM") and manages and allocates resources between the Americas and International segments. Consistent with this decision-making process, the CODM uses financial information disaggregated between the Americas and International segment for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM evaluates segment business performance based primarily on net sales and gross profit. The CODM considers budget-to-actual variances on a monthly basis for both measures when making decisions about allocating capital and personnel to the segments and also uses segment gross profit for evaluating product pricing.

------

**Table of Contents**

Information about the Company's operations by operating segment as of and for the three and six months ended June 30, 2025 and 2024 is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Net sales** | $**168759** | $**144116** | $**299680** | $**255814** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas | 141961 | 124502 | 254561 | 220593 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 26798 | 19614 | 45119 | 35221 |
| **Cost of goods sold**  | $**107494** | $**85379** | $**190330** | $**149900** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas | 90915 | 72295 | $161203 | $127514 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 16579 | 13084 | $29127 | $22386 |
| **Gross profit** | $**61265** | $**58737** | $**109350** | $**105914** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas | 51046 | 52208 | 93358 | 93080 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 10219 | 6529 | 15992 | 12834 |

---

---

| | | |
|:---|:---|:---|
| | **As of**<br> **June 30,** | **As of December 31,** |
| | **2025** | **2024** |
| **Total segment assets** | $**421077** | $**362381** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas | 278549 | 241894 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International | 142528 | 120487 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| **Reconciliation:** | **2025** | **2024** | **2025** | **2024** |
| **Total gross profit** | $61265 | $58737 | $109350 | $105914 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative expenses | 36143 | 28756 | 64935 | 56974 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from operations | $25122 | $29981 | $44415 | $48940 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain/(loss) on derivative instruments | 1067 | (5963) | 3884 | (8488) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency gain/(loss) | 482 | (136) | 1062 | (78) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 1500 | 1627 | 3018 | 3150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income |  |  | 155 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income before income taxes | $28171 | $25509 | $52534 | $43524 |

---

------

**Table of Contents**

*Geographic Data:* 

The following table provides information related to the Company's net sales by country, which is presented on the basis of the location that revenue from customers is recorded:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| United States | $235813 | $205561 |
| United Kingdom  | 31403 | 25862 |
| All other countries<sup>(1)</sup> | 32464 | 24391 |
| Net sales | $299680 | $255814 |

---

___________

(1) No individual country is greater than 10% of total net sales for the six months ended June 30, 2025 and 2024.

The following table provides information related to the Company's property and equipment, net by country:

---

| | | |
|:---|:---|:---|
| | **June 30,<br>2025** | **December 31,<br>2024** |
| Singapore | $1528 | $1280 |
| United States | $1163 | $758 |
| United Kingdom | 629 | 173 |
| All other countries<sup>(1)</sup> | 141 | 140 |
| Property and equipment, net | $3461 | $2351 |

---

___________

(1) No individual country is greater than 10% of total property and equipment, net as of June 30, 2025 and December 31, 2024.

**15. RELATED PARTY TRANSACTIONS**

*Director Nominee Agreement* - On May 24, 2022, a member of the Board appointed as a nominee under the Investor Rights Agreement by Verlinvest Beverages SA ("Verlinvest"), a stockholder of the Company, entered into a nominee agreement instructing the Company to pay all cash and equity compensation earned in connection with his board of director service to Verlinvest. Based on the aforementioned nominee agreement, until the termination of the agreement, RSUs granted to this director were held by him as a nominee for Verlinvest and, upon vesting of the RSUs, the shares were transferred to Verlinvest. The nominee agreement terminated on June 3, 2025 and is no longer in effect. Following termination of the agreement, the director will receive all cash and equity compensation directly. The nominee agreement was primarily between the director and Verlinvest. The Company was a party to this arrangement solely to agree to the manner in which it would satisfy the compensation obligations to this director.

*Registration Rights and Underwriting Agreements* - Under the Registration Rights agreement by and among the Company, Verlinvest, and certain other investors, in connection with each demand registration, piggyback or shelf offering, the Company agreed to reimburse the holders of registrable securities for the reasonable fees and disbursements of not more than one law firm. As part of the two secondary offerings during 2023, the Company also entered into underwriting agreements, to which Verlinvest was a party. In connection with the secondary share offering by Verlinvest in May 2023, Verlinvest agreed to waive its right to reimbursement of legal fees for its counsel in the fourth quarter of 2023, and those expenses, in the amount of $140, were not reimbursed by the Company. In connection with the secondary share offering by Verlinvest in November 2023, in April 2024, Verlinvest agreed to waive its right to reimbursement of legal fees for its counsel, and those expenses, in the amount of $324, were not reimbursed by the Company.

------

**Table of Contents**

**16. INVESTMENT IN UNCONSOLIDATED JOINT VENTURE**

In accordance with ASC 323, Investments - Equity Method and Joint Ventures, investments in entities over which the Company does not have a controlling financial interest but has significant influence are accounted for using the equity method, with the Company's share of earnings or losses reported in the condensed consolidated statements of operations.

Through one of its subsidiaries, the Company has a 60% joint venture interest in a company, Coco Ventures Limited, which provides for the development, marketing, distribution and branding of coconut water-based products under the Vita Coco brand in China. Coco Ventures Limited purchases coconut water products from the Company. The Company acquired this interest on August 2, 2024, the date on which the Company obtained significant influence, for $585 to be paid in cash within one year. The Company recorded the initial investment in the joint venture upon cash payment. Since the Company is deemed not to have a controlling interest in Coco Ventures Limited, the Company's investment is accounted using the equity method of accounting in accordance with ASC 323. In the six months ended June 30, 2025, the Company contributed $104 as a part of initial capital funding. Coco Ventures Limited commenced operations in February 2025.

**17. LEASES**

In August 2024, the Company signed a lease agreement for a new office in New York, New York. The Company's existing New York office lease expired on April 30, 2025, and was extended to October 31, 2025 to allow for a smooth transition to the Company's new New York office. The operating lease commenced on January 1, 2025, ending in December 2034, with an option to extend for an additional two years. The Company recognized right-of-use assets and lease liabilities of $10,002 and $11,692, respectively, upon lease commencement on the Company's condensed consolidated balance sheet. Additionally, upon signing the agreement, the Company was required to establish a letter of credit of $920 as a security deposit which may be used in case of delinquency, which is accounted for as restricted cash. In addition, in November 2024, the Company signed a lease agreement for a new office in London, United Kingdom. The operating lease commenced on January 2, 2025 and terminates in December 2030. The Company recognized right-of-use assets and lease liabilities of $1,140 and $1,252 respectively, upon lease commencement on the Company's condensed consolidated balance sheet. In April 2025, the Company signed an agreement for a new office in Singapore. The operating lease commenced on April 1, 2025 and terminates in June 2030. The Company recognized right-of-use assets and lease liabilities of $1,564 and $1,564 respectively, upon lease commencement on the Company's condensed consolidated balance sheet.

The following table summarizes supplemental balance sheet information for the Company's operating leases:

---

| | | | |
|:---|:---|:---|:---|
| | **Line Item in Balance Sheet** | **As of June 30, 2025** | **As of December 31, 2024** |
| &nbsp;&nbsp;Operating lease right-of-use assets | Right-of-use assets | $12222 | $385 |
| &nbsp;&nbsp;Current portion of operating lease liabilities | Accrued expenses and other current liabilities  | $769 | $422 |
| &nbsp;&nbsp;Non-current portion of operating lease liabilities | Operating lease liabilities, long-term | $13996 | $— |

---

------

**Table of Contents**

***Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.***

*You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and filed with the Securities and Exchange Commission ("SEC") on February 26, 2025 (the "Form 10-K"). This discussion contains forward-looking statements based upon current plans, expectations and beliefs involving risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part I, Item 1A, "Risk Factors" of the Form 10-K and other factors set forth in the Form 10-K and Quarterly Reports on Form 10-Q.*

 **Overview**

The Vita Coco Company pioneered packaged coconut water in 2004 and we have extended our business into other categories. Our mission is to deliver great tasting, natural and nutritious products that we believe are better for consumers and better for the world. We are one of the largest brands globally in the coconut and other plant waters category, and a large supplier of private label coconut water.

Our branded portfolio is led by our *Vita Coco* brand, which is the leader in the coconut water category in the United States, and also includes coconut oil, juice, and milk offerings. Our other brands include *Ever & Ever*, a sustainably packaged water, and *PWR LIFT*, a protein-infused fitness drink. We also previously offered *Runa*, a plant-based energy drink inspired by the guayusa plant native to Ecuador, which we ceased selling in December 2023. We supply private label products to key retailers in both the coconut water and coconut oil categories. Additionally, we generate revenue from bulk product sales to beverage and food companies.

As of June 30, 2025, we source our coconut water from a diversified global network of 16 factories across six countries supported by thousands of coconut farmers. As we do not own any of these factories, our supply chain is a fixed asset-lite model designed to better react to changes in the market or consumer preferences. We also work with co-packers in U.S., Canada, Mexico, and Europe to support local packaging and repacking of our products to better service our customers' needs.

*Vita Coco* is available in over 35 countries, with our primary markets located in North America, the United Kingdom and Germany. Our primary markets for private label are North America and Europe. Our products are distributed primarily through club, food, drug, mass, convenience, e-commerce and food service channels. Our products are also available in a variety of on-premise locations such as corporate offices, fitness clubs, airports and educational institutions.

**Key Factors Affecting Our Performance** 

We believe that our performance and future success depend on a number of factors that present significant opportunities for us. There have been no material changes to such factors from those described in the Form 10-K under the heading "Key Factors Affecting our Performance" and the changes noted below. Those factors also pose risks and challenges, including those discussed in Part I, Item 1A. "Risk Factors" of the Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Uncertainty in the macroeconomic environment resulting from geopolitical and economic instability (including the effects of current wars and other international conflicts) and variability in interest rates, foreign exchange rates, tariffs and other import related fees, and inflationary cost environments may affect our global supply chain. Additionally, as further discussed below, the extent and duration of tariffs imposed by the U.S. government on other countries and reciprocal tariffs placed on U.S. goods in response thereto remains uncertain and may depend on various factors, including negotiations and relationships between the U.S. and affected countries, tariff exemptions, negative sentiment toward U.S. companies and products, and availability of domestic alternatives in our supply chain. It is not currently possible to ascertain the overall impact of these macroeconomic uncertainties on our business, results of operations, financial condition or liquidity. Future events and effects related to these macroeconomic uncertainties cannot be determined with precision and actual results could significantly differ from estimates or forecasts. For a further discussion of the risks and challenges posed by these events, please see Part I, Item 1A. "Risk Factors" of the Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• During the first quarter of 2025, the U.S. government announced tariffs on certain imports, including imports from Mexico, and Canada. We currently believe that our production in Mexico and Canada is exempt from these tariffs under the United States-Mexico-Canada Agreement ("USMCA"). On April 2, 2025, the U.S. announced a new

------

**Table of Contents**

universal baseline tariff of 10%, plus significant additional country-specific tariffs for select trading partners, on all U.S. imports. The reciprocal tariffs were subsequently paused for 90 days on most countries; however the 10% baseline tariff is currently being applied, which has increased our cost of goods sold. The baseline tariffs are being challenged in the U.S. legal system and it is unclear whether the tariffs will be upheld and remain in place, or if they will be struck down by the courts. Currently, we are assuming for purposes of our business operations that the baseline tariffs will be in effect indefinitely. However, the uncertainty around the long-term tariff rates that could be applied to our importation of products into the U.S. presents significant challenges to our operations and supply chain, and may result in future results being significantly different than any outlook given. We cannot predict what additional actions might be considered or implemented by the U.S. or its trade partners, particularly in the current geopolitical environment. The uncertainty could also cause disturbances in ocean shipping capacity that could affect our ability to secure ocean freight containers for our products, and create inflationary effects on our costs, in addition to the direct impact of tariffs. We are closely monitoring the evolving tariff landscape and attempting to mitigate these impacts, including using pricing adjustments, sourcing strategies and other cost-mitigation measures. However, there can be no assurance that we will be able to fully mitigate the impacts of such tariffs or that the imposition of tariffs, and the resulting economic impact on the U.S. market and consumer, will not be material to our financial results. We primarily source from the Philippines and Brazil, with additional sourcing from Sri Lanka, Thailand, Malaysia, Vietnam, Canada, and Mexico. Recently, the administration delayed the reciprocal tariff implementation, but then announced significant proposed tariffs on certain of these countries replacing the initially announced reciprocal tariffs, which may further increase our cost of goods sold. In particular, a 50% tariff has been proposed for Brazil, which was not initially listed as one of the proposed reciprocal tariffs. At this time, the overall impact on our business related to tariffs remains uncertain and depends on multiple factors, including the timing, duration and size of any tariffs, future changes to tariff rates, scope, or enforcement of such tariffs, reciprocal measures by impacted trade partners, inflationary effects, changes to consumer purchasing behavior, and the effectiveness of our responses in managing these challenges. These tariff actions, retaliatory measures, or other trade restrictions, could materially and adversely affect our business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our sales to one of our major customers include branded and private label product. As discussed in our Form 10-K, the private label coconut oil business with this customer discontinued in early 2024 and we expect private label coconut water net sales in 2025 with this customer to be impacted by the loss of some regions, which started primarily in the second quarter of 2025.

**Components of Our Results of Operations**

***Net Sales***

We generate revenue through the sale of our *Vita Coco* branded coconut water, Private Label, and Other products in the Americas and International segments. Our sales are predominantly made to distributors or to retailers for final sale to consumers through retail channels, which includes sales to traditional brick and mortar retailers, who may also resell our products through their own online platforms. Our revenue is recognized net of allowances for returns, discounts, credits, and any taxes collected from consumers.

We provide trade promotions and sales discounts to its customers and distributors. Since these sales promotions and sales discounts do not meet the criteria for a distinct good or service, they are primarily accounted for as a reduction of revenue and include payments to customers and distributors for performing activities on our behalf, such as payments for in-store displays, payments to gain distribution of new products, payments for shelf space and discounts to promote lower retail prices. The accompanying condensed consolidated financial statements include accruals for these promotions and discounts. The accruals are made for invoices that have not yet been received as of the end of the reporting period and are recorded as a reduction of sales, and are based on contract terms and our historical experience with similar programs and require management judgment with respect to estimating customer and consumer participation and performance levels.

***Cost of Goods Sold***

Cost of goods sold includes the costs of the products sold to customers, inbound and outbound shipping and handling costs, freight and duties, shipping and packaging supplies, and warehouse fulfillment costs.

------

**Table of Contents**

***Gross Profit and Gross Margin***

Gross profit is net sales less cost of goods sold, and gross margin is gross profit as a percentage of net sales. Gross profit has been, and will continue to be, affected by various factors, including the mix of products we sell, the channels through which we sell our products, the promotional environment in the marketplace, manufacturing costs, commodity prices, warehouse costs, and transportation rates. We expect that our gross margin will fluctuate from period to period depending on the interplay of these variables.

Management believes gross margin provides investors with useful information related to the profitability of our business prior to considering the operating costs incurred. Management uses gross profit and gross margin as key measures in making financial, operating, and planning decisions and in evaluating our performance.

***Operating Expenses***

***Selling, General and Administrative Expenses***

Selling, general and administrative expenses ("SG&A") include marketing expenses, promotional expenses, and general and administrative expenses. Marketing and promotional expenses consist primarily of costs incurred promoting and marketing our products and are primarily driven by investments to grow our business and retain customers. General and administrative expenses include payroll, employee benefits, stock-based compensation, broker commissions and other headcount-related expenses associated with supply chain & operations, finance, information technology, human resources and other administrative-related personnel, as well as general overhead costs of the business, including research and development for new innovations, rent and related facilities and maintenance costs, depreciation and amortization, and legal, accounting, and professional fees.

**Other Income (Expense), Net**

***Unrealized Gain/(Loss) on Derivative Instruments***

We are subject to foreign currency risks as a result of our inventory purchases and intercompany transactions. In order to mitigate the foreign currency risks, we and our subsidiaries enter into foreign currency exchange contracts which are recorded at fair value. Unrealized gain/(loss) on derivative instruments consists of gains or losses on such foreign currency exchange contracts which are unsettled as of period end. See Part I, Item 3 "Quantitative and Qualitative Disclosures about Market Risk—Foreign Currency Exchange Risk*"* for further information.

***Foreign Currency Gain/(Loss)***

Our reporting currency is the U.S. dollar. We maintain the financial statements of each entity within the group in its local currency, which is also the entity's functional currency. Foreign currency gain/(loss) represents the transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency. See "—Quantitative and Qualitative Disclosures about Market Risk—Foreign Currency Exchange Risk*"* for further information.

***Interest Income***

Interest income consists of interest income earned on our cash and cash equivalents, and money market funds.

***Income Tax Expense***

We are subject to federal and state income taxes in the United States and taxes in foreign jurisdictions in which we operate. We recognize deferred tax assets and liabilities based on temporary differences between the financial reporting and income tax bases of assets and liabilities using statutory rates. We regularly assess the need to record a valuation allowance against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

**Operating Segments**

We operate in two reporting segments:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Americas***—The Americas segment is comprised of our operations in the Americas region, primarily in the United States and Canada.

------

**Table of Contents**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***International***—The International segment is comprised of our operations primarily in Europe, the Middle East, and the Asia Pacific regions, which includes the Company's procurement arm.

Each segment derives its revenues from the following product categories:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Vita Coco Coconut Water***—This product category consists of all branded coconut water product offerings under the *Vita Coco* labels, where the majority ingredient is coconut water. For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Private Label*** —This product category consists of all private label product offerings, which includes coconut water and coconut oil. The Company determined the production and distribution of private label products represents a distinct performance obligation. Since there is no alternative use for these products and the Company has the right to payment for performance completed to date, the Company recognizes the revenue for the production of these private label products over time as the production for open purchase orders occurs, which may be prior to any shipment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• ***Other—***This product category consists of all other products, which includes *Vita Coco* product extensions beyond coconut water, consisting of coconut milk products, including *Vita Coco* Treats; *Ever & Ever* and *PWR LIFT* product offerings; *Vita Coco* coconut oil sold internationally; and other revenue transactions (e.g., bulk product sales). For these products, control is transferred upon customer receipt, at which point the Company recognizes the transaction price for the product as revenue.

**Results of Operations**

**Comparison of the Three and Six Months Ended June 30, 2025 and 2024**

The following table summarizes our results of operations for the three and six months ended June 30, 2025 and 2024, respectively:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands)** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| **(in thousands)** | **2025** | **2024** | **2025** | **2024** |
| Net sales | $168759 | $144116 | $299680 | $255814 |
| Cost of goods sold | 107494 | 85379 | 190330 | 149900 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 61265 | 58737 | 109350 | 105914 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general, and administrative | 36143 | 28756 | 64935 | 56974 |
| Income from operations | 25122 | 29981 | 44415 | 48940 |
| Other income (expense) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain/(loss) on derivative instrument | 1067 | (5963) | 3884 | (8488) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency gain/(loss) | 482 | (136) | 1062 | (78) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest income | 1500 | 1627 | 3018 | 3150 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income |  |  | 155 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense) | 3049 | (4472) | 8119 | (5416) |
| Income before income taxes | 28171 | 25509 | 52534 | 43524 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 5263 | 6416 | 10744 | 10193 |
| Net income | $22908 | $19093 | $41790 | $33331 |

---

------

**Table of Contents**

***Net Sales***

The following table provides a comparative summary of net sales by operating segment and product category:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **(in thousands)** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Change** | **Change** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Change** | **Change** |
| **(in thousands)** | **2025** | **2024** | **Amount** | **Percentage** | **2025** | **2024** | **Amount** | **Percentage** |
| **Americas segment** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vita Coco Coconut Water | $120450 | $98494 | $21956 | 22.3% | $206568 | $168016 | $38552 | 22.9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Private Label | 14685 | 23135 | (8450) | (36.5)% | 35882 | 47408 | (11526) | (24.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 6826 | 2873 | 3953 | 137.6% | 12111 | 5169 | 6942 | 134.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | $141961 | $124502 | $17459 | 14.0% | $254561 | $220593 | $33968 | 15.4% |
| **International segment** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vita Coco Coconut Water | $19882 | $13952 | $5930 | 42.5% | 33059 | 23617 | $9442 | 40.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Private Label | 6222 | 4816 | 1406 | 29.2% | 10981 | 9968 | 1013 | 10.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 694 | 846 | (152) | (18.0)% | 1079 | 1636 | (557) | (34.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | $26798 | $19614 | $7184 | 36.6% | $45119 | $35221 | $9898 | 28.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $168759 | $144116 | $24643 | 17.1% | $299680 | $255814 | $43866 | 17.1% |

---

For the three months ended June 30, 2025, the primary driver of the consolidated net sales increase of 17.1% was strong *Vita Coco* Coconut Water volume growth. *Vita Coco* Coconut Water net sales increased 24.8%, with a case equivalents ("CE") volume increase of 20.9% and growth in the Other category, driven by the U.S. rollout of *Vita Coco* Treats. This was partially offset by a 25.2% decrease in private label net sales, which was due largely to the loss of private label coconut water service regions for multiple customers that started in the first six months of 2025. For the six months ended June 30, 2025, the consolidated net sales increase of 17.1% was driven by *Vita Coco* Coconut Water, which had a 25.0% net sales increase, with a case equivalents CE volume increase of 22.7%. This was partially offset by private label net sales decline of 18.3% resulting from the loss of private label coconut water service regions for multiple customers in addition to the transition out of private label coconut oil sales to a major customer that began in the first quarter of 2024.

*Volume in Case Equivalents* 

The following table provides a comparative summary of the percentage change in our volume in CE for the three and six months ended June 30, 2025 compared to the three and six months ended June 30, 2024, by operating segment and product category:

---

| | | | |
|:---|:---|:---|:---|
| | **Percentage Change - Three Months Ended June 30, 2025 vs. 2024** | **Percentage Change - Three Months Ended June 30, 2025 vs. 2024** | **Percentage Change - Three Months Ended June 30, 2025 vs. 2024** |
| | **Americas** | **International** | **Total**  |
| &nbsp;&nbsp;Vita Coco Coconut Water | 20.6% | 22.9% | 20.9% |
| &nbsp;&nbsp;Private Label | (34.0)% | 26.5% | (21.7)% |
| &nbsp;&nbsp;Other | 212.7% | 54.2% | 202.2% |
| Total volume (CE) | 12.2% | 24.1% | 14.1% |
|  | **Percentage Change - Six Months Ended June 30, 2025 vs. 2024** | **Percentage Change - Six Months Ended June 30, 2025 vs. 2024** | **Percentage Change - Six Months Ended June 30, 2025 vs. 2024** |
|  | **Americas** | **International** | **Total**  |
| &nbsp;&nbsp;Vita Coco Coconut Water | 21.7% | 27.7% | 22.7% |
| &nbsp;&nbsp;Private Label | (18.5)% | 20.3% | (10.8)% |
| &nbsp;&nbsp;Other | 202.0% | 27.0% | 189.3% |
| Total volume (CE) | 15.2% | 25.4% | 16.9% |

---

*Note: A CE is a standard volume measure used by management, which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil.* 

------

**Table of Contents**

\*International, Other excludes minor volume that is treated as zero CE.

*Americas Segment* 

Americas net sales increased $17.5 million, or 14.0%, to $142.0 million for the three months ended June 30, 2025 from $124.5 million for the three months ended June 30, 2024. The increase was primarily driven by CE volume growth of 20.6% of *Vita Coco* Coconut Water, partially offset by volume lost due to the loss of private label coconut water service regions for several customers that started in the first six months 2025. Americas net sales increased $34.0 million, or 15.4%, to $254.6 million for the six months ended June 30, 2025 from $220.6 million for the six months ended June 30, 2024. The increase was primarily driven by CE volume growth of 21.7% of *Vita Coco* Coconut Water, offset by the private label decline.

*Vita Coco* Coconut Water net sales increased $22.0 million, or 22.3%, to $120.5 million for the three months ended June 30, 2025, from $98.5 million for the three months ended June 30, 2024. The increase was the result of CE volume growth of 20.6% due to increased demand. *Vita Coco* Coconut Water net sales increased $38.6 million, or 22.9%, to $206.6 million for the six months ended June 30, 2025, from $168.0 million for the six months ended June 30, 2024. The increase was the result of CE volume growth of 21.7% due to strong consumer demand.

Private label net sales decreased $8.5 million, or 36.5%, to $14.7 million for the three months ended June 30, 2025, from $23.1 million for the three months ended June 30, 2024, due to a decrease in the private label business as outlined above, resulting in CE volume decrease of 34.0%. Private label net sales decreased $11.5 million, or 24.3%, to $35.9 million for the six months ended June 30, 2025, from $47.4 million for the six months ended June 30, 2024. The decrease was the result of CE volume decline of 18.5% due to the aforementioned losses of private label coconut oil and coconut water business.

Net sales from Other products increased by $4.0 million, or 137.6%, to $6.8 million for the three months ended June 30, 2025 from $2.9 million for the three months ended June 30, 2024, primarily due to the national rollout of *Vita Coco* Treats in the U.S. Net sales from Other products increased by $6.9 million, or 134.3%, to $12.1 million for the six months ended June 30, 2025 from $5.2 million for the six months ended June 30, 2024, driven by CE volume increase of 202.0%, driven by the rollout of *Vita Coco* Treats.

*International Segment*

International net sales increased by $7.2 million, or 36.6%, to $26.8 million for the three months ended June 30, 2025, from $19.6 million for the three months ended June 30, 2024. The increase of 24.1% in CE volume is primarily driven by growth in Germany and the United Kingdom, partially offset by softness in China. International net sales increased by $9.9 million, or 28.1%, to $45.1 million for the six months ended June 30, 2025, from $35.2 million for the six months ended June 30, 2024. The increase is primarily driven by CE volume growth of 25.4% in Germany and United Kingdom partially offset by softness in China.

*Vita Coco* Coconut Water net sales increased by $5.9 million, or 42.5%, to $19.9 million for the three months ended June 30, 2025, from $14.0 million for the three months ended June 30, 2024. The increase was driven by higher volume in Europe due to strong demand for our products, along with some pricing and foreign exchange rate benefits. *Vita Coco* Coconut Water net sales increased by $9.4 million, or 40.0%, to $33.1 million for the six months ended June 30, 2025, from $23.6 million for the six months ended June 30, 2024. The increase was primarily driven by strong CE volume growth in Europe coupled with pricing benefits.

Private label net sales increased $1.4 million, or 29.2%, to $6.2 million for the three months ended June 30, 2025 from $4.8 million for the three months ended June 30, 2024. The increase was driven primarily by private label coconut water CE volume growth in Europe, which was partially offset by a decrease in the private label coconut oil business in Asia. Private label net sales increased $1.0 million, or 10.2%, to $11.0 million for the six months ended June 30, 2025 from $10.0 million for the six months ended June 30, 2024. The increase was driven primarily by CE volume growth in Europe private label coconut water sales, partially offset by a decrease in private label coconut oil volume.

Net sales from Other products decreased 18.0% and 34.0% for the three and six months ended June 30, 2025, respectively, compared to the same periods in the prior year, primarily driven by the decrease in sales of *Vita Coco* coconut oil.

------

**Table of Contents**

***Gross Profit***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($ in thousands)** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Change** | **Change** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Change** | **Change** |
| **($ in thousands)** | **2025** | **2024** | **Amount** | **Percentage** | **2025** | **2024** | **Amount** | **Percentage** |
| **Cost of goods sold** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas segment | $90915 | $72295 | $18620 | 25.8% | $161203 | $127514 | $33689 | 26.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International segment | 16579 | 13084 | 3495 | 26.7% | 29127 | 22386 | 6741 | 30.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of goods sold | $107494 | $85379 | $22115 | 25.9% | $190330 | $149900 | $40430 | 27.0% |
| **Gross profit** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas segment | $51046 | $52208 | $(1162) | (2.2)% | $93358 | $93080 | $278 | 0.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International segment | 10219 | 6529 | 3690 | 56.5% | 15992 | 12834 | 3158 | 24.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross profit | $61265 | $58737 | $2528 | 4.3% | $109350 | $105914 | $3436 | 3.2% |
| **Gross margin** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Americas segment | 36.0% | 41.9% |  | (5.9)% | 36.7% | 42.2% |  | (5.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;International segment | 38.1% | 33.3% |  | 4.8% | 35.4% | 36.4% |  | (1.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidated | 36.3% | 40.8% |  | (4.5)% | 36.5% | 41.4% |  | (4.9)% |

---

On a consolidated basis, cost of goods sold increased $22.1 million, or 25.9%, to $107.5 million for the three months ended June 30, 2025, from $85.4 million for the three months ended June 30, 2024. On a consolidated and segment basis, the increase was primarily driven by higher CE volume and higher rates for finished goods and transportation costs and the initial impact of baseline tariffs. Cost of goods sold increased by $40.4 million, or 27.0%, to $190.3 million for the six months ended June 30, 2025, from $149.9 million for the six months ended June 30, 2024. On a consolidated basis, the increase was primarily related to increased CE volume and higher finished goods and transportation costs, and to a lesser extent, the initial impact of baseline tariffs.

For the three months ended June 30, 2025, consolidated gross profit increased $2.5 million, or 4.3%, to $61.3 million, from $58.7 million for the three months ended June 30, 2024, primarily driven by higher CE volume. The increase was partially offset by increased rates for finished goods and transportation costs and the initial impact of baseline tariffs, these costs also resulted in gross margin decline, which was partially offset by branded coconut water pricing and favorable product mix. For the six months ended June 30, 2025, consolidated gross profit increased $3.4 million, or 3.2%, to $109.4 million, from $105.9 million for the six months ended June 30, 2024, also primarily driven by higher CE volume, and partially offset by increased rates for finished goods and transportation costs and the initial impact of baseline tariffs. Similar to the quarterly results, higher year-on-year ocean freight and finished goods costs resulted in a decrease in gross margin, partially offset by branded coconut water pricing and favorable product mix.

***Operating Expenses***

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($ in thousands)** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Change** | **Change** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Change** | **Change** |
| **($ in thousands)** | **2025** | **2024** | **Amount** | **Percentage** | **2025** | **2024** | **Amount** | **Percentage** |
| Selling, general, and administrative | $36143 | $28756 | $7387 | 25.7% | 64935 | 56974 | 7961 | 14.0% |

---

*Selling, General and Administrative Expenses* 

For the three months ended June 30, 2025, SG&A increased $7.4 million, or 25.7%, versus the three months ended June 30, 2024. The increase was primarily driven by an increase of $3.1 million in marketing expense primarily due to new product awareness campaigns for *Vita Coco* Treats, $2.7 million in personnel-related expenses, $0.9 million in higher reserves for bad debt, and $0.4 million related to an overlap of rent expense for the new New York office with the current New York office. During the six months ended June 30, 2025, SG&A increased $8.0 million, or 14.0%, versus the six months ended June 30, 2024. The increase was primarily driven by an increase of $4.6 million in personnel-related expenses and $3.0 million in marketing expense due to new product awareness campaigns for *Vita Coco* Treats, $0.8 million of higher reserves for bad debt expenses, $0.7 million related to the overlap of rent expense for the new New York office with the current New York office. The increases were partially offset by a reduction of $2.3 million in sales related expenses.

------

**Table of Contents**

*Other Income (Expense), Net* 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($ in thousands)** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Change** | **Change** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Change** | **Change** |
| **($ in thousands)** | **2025** | **2024** | **Amount** | **Percentage** | **2025** | **2024** | **Amount** | **Percentage** |
| Unrealized gain/(loss) on derivative instruments | $1067 | $(5963) | $7030 | n/m | $3884 | $(8488) | $12372 | n/m |
| Foreign currency gain/(loss) | 482 | (136) | 618 | n/m | 1062 | (78) | 1140 | n/m |
| Interest income | 1500 | 1627 | (127) | (7.8%) | 3018 | 3150 | (132) | (4.2%) |
| Other income |  |  |  | n/m | 155 |  | 155 | n/m |
|  | $3049 | $(4472) | $7521 | n/m | $8119 | $(5416) | $13535 | n/m |

---

*Unrealized Gain/(Loss) on Derivative Instruments* 

For the three months ended June 30, 2025 and 2024, we recorded gains of $1.1 million and losses of $6.0 million, respectively, for the mark-to-market changes in fair value on the outstanding derivative instruments for forward foreign currency exchange contracts, with the largest gain for the three months ended June 30, 2025 related to the contracts hedging the BRL and THB. For the six months ended June 30, 2025 and 2024, we recorded gains of $3.9 million and losses of $8.5 million, respectively, for the mark-to-market changes in fair value on the outstanding derivative instruments for forward foreign currency exchange contracts, with the largest gain for the six months ended June 30, 2025 related to the contracts hedging the BRL and THB, partially offset by loss on GBP, CAD, and EUR hedges.

*Foreign Currency Gain/(Loss)*

For the three months ended June 30, 2025, the change in foreign currency gain was $0.6 million as compared to June 30, 2024. For the six months ended June 30, 2025, the change in foreign currency gain was $1.1 million as compared to June 30, 2024. The change in all periods was a result of movements in various foreign currency exchange rates related to transactions denominated in currencies other than the functional currency. See "Quantitative and Qualitative Disclosures about Market Risk - *Foreign Currency Exchange Risk*" for further information.

*Interest Income*

For the three months ended June 30, 2025, interest income decreased $0.1 million compared to June 30, 2024 primarily due to lower interest rates in the 2025 period compared to the 2024 period. For the six months ended June 30, 2025, interest income decreased $0.1 million as compared to June 30, 2024. The decrease in interest income was due to lower interest rates compared to prior year.

*Other Income* 

For the six months ended June 30, 2025, Other income of $0.2 million is due to the sale of intellectual property.

*Income Tax Expense* 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **($ in thousands)** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Change** | **Change** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Change** | **Change** |
| **($ in thousands)** | **2025** | **2024** | **Amount** | **Percentage** | **2025** | **2024** | **Amount** | **Percentage** |
| Income tax expense | 5263 | 6416 | $(1153) | (18.0)% | $10744 | $10193 | $551 | 5.4% |
| Tax rate | 18.7% | 25.2% |  |  | 20.5% | 23.4% |  |  |

---

Our quarterly income tax provision is based on an estimated annual effective tax rate applied to our consolidated year-to-date pre-tax income or loss. The effective income tax rate is based upon the estimated income for the year, the composition of that income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies.

------

**Table of Contents**

For the six months ended June 30, 2025 and 2024, our effective tax rate was 20.5% and 23.4%, respectively. The effective tax rate for the current period is lower than the U.S. statutory rate of 21% primarily as a result of discrete items recorded during the period. The effective tax rate for the period ending June 30, 2024 was higher than the U.S. statutory rate of 21% primarily as a result of state income taxes for the U.S. entity. The change in effective tax rates between the periods is primarily driven by the jurisdictional mix of the Company's pre-tax profits and the relative impact of other non-deductible expenses in relation to the pre-tax profits.

***Non-GAAP Financial Measures***

EBITDA and Adjusted EBITDA are supplemental non-GAAP financial measures that are used by management and external users of our financial statements, such as industry analysts, investors and lenders. These non-GAAP measures should not be considered as alternatives to net income as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP and should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

These non-GAAP measures are a key metric used by management and our Board to assess our financial performance. We present these non-GAAP measures because we believe they assist investors in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company.

We define EBITDA as net income before interest, taxes, depreciation, and amortization. Adjusted EBITDA is defined as EBITDA with adjustments to eliminate the impact of certain items, including certain non-cash and other items, that we do not consider representative of our ongoing operating performance.

A reconciliation from net income to EBITDA and Adjusted EBITDA is set forth below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Net income | 22908 | 19093 | 41790 | 33331 |
| Depreciation and amortization | 206 | 182 | 408 | 344 |
| Interest income | (1500) | (1627) | (3018) | (3150) |
| Income tax expense | 5263 | 6416 | 10744 | 10193 |
| **EBITDA** | 26877 | 24064 | 49924 | 40718 |
| Stock-based compensation (a) | 2962 | 2399 | 5148 | 4508 |
| Unrealized (gain)/loss on derivative instruments (b) | (1067) | 5963 | (3884) | 8488 |
| Foreign currency (gain)/loss (b) | (482) | 136 | (1062) | 78 |
| Secondary Offering Costs (c) |  | (324) |  | (324) |
| Other adjustments (d) | 952 |  | 1621 |  |
| **Adjusted EBITDA** | $29242 | $32238 | 51747 | $53468 |

---

____________

(a)Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.

(b)Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.

(c)The amounts for the three and six months ended June 30, 2024 relate to an expense waiver of certain costs incurred during the November 9, 2023 block trade. The Company did not receive any proceeds from the sale of the shares. For additional information regarding the expense waiver for the three and six months ended June 30, 2024, see Note 15, *Related Party Transactions*, in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

(d)The three months ended June 30, 2025 includes $0.6 million related to a one-time 2023 incentive program that is measured based on full-year 2025 performance structured differently from our other ongoing employee incentive

------

**Table of Contents**

programs, and $0.4 million of rent expense related to our new New York City office that overlap with our current New York City office rent charges. The six months ended June 30, 2025 includes $1.2 million related to a one-time 2023 incentive program that is measured based on full-year 2025 performance structured differently from our other ongoing employee incentive programs, and $0.7 million of dual rent expense related to our New York City office. These amounts were offset by $0.1 million of partial recoveries of prepaid inventory from a supplier (refer to the Form 10-K for further details) and a gain of $0.2 million from a sale of intellectual property.

**Liquidity and Capital Resources** 

Since our inception, we have financed our operations primarily through cash generated from our business operations and proceeds on borrowings through our credit facilities and term loans. We had $167.0 million and $164.7 million of cash and cash equivalents as of June 30, 2025 and December 31, 2024, respectively. From time to time, we may supplement our liquidity needs with incremental borrowing capacity under the 2020 Credit Facility.

Considering recent market conditions and our business assumptions, we have reevaluated our operating cash flows and cash requirements and believe that current cash, cash equivalents, future cash flows from operating activities and cash available under our 2020 Credit Facility will be sufficient to meet our anticipated cash needs, including working capital needs, capital expenditures and contractual obligations for at least 12 months from the issuance date of the condensed consolidated financial statements included herein and the foreseeable future.

Our future capital requirements will depend on many factors, including our revenue growth rate, our working capital needs primarily for inventory build, our global footprint, the expansion of our marketing activities, the timing and extent of spending to support product development efforts, the introduction of new and enhanced products and the continued market consumption of our products, as well as any shareholder distribution either through equity buybacks or dividends. Our asset-lite operating model has historically provided us with a low cost, nimble, and scalable supply chain, which allows us to adapt to changes in the market or consumer preferences while also efficiently introducing new products across our platform. We may seek additional equity or debt financing in the future in order to acquire or invest in complementary businesses, products and/or new IT infrastructures. In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to expand our operations and invest in continued product innovation, we may not be able to compete successfully, which would harm our business, operations and financial condition.

***Cash Flows***

The following tables summarize our sources and uses of cash:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Change** | **Change** |
| | **2025** | **2024** | **Amount** | **Percentage** |
| **($ in thousands)** |  |  |  |  |
| Cash flows provided by (used in): |  |  |  |  |
| Operating activities | $12010 | $26652 | $(14642) | (54.9%) |
| Investing activities | (1508) | (414) | (1094) | n/m |
| Financing activities | (9081) | (8562) | (519) | 6.1% |
| Effects of exchange rate changes on cash and cash equivalents | 961 | (106) | 1067 | n/m |
| Net (decrease)/increase in cash and cash equivalents | $2382 | $17570 | $(15188) | 86.4% |

---

***Operating Activities***

Our main source of operating cash is payments received from our customers. Our primary use of cash in operating activities are for cost of goods sold and SG&A expenses.

During the six months ended June 30, 2025, cash provided by operating activities decreased $14.6 million compared to the six months ended June 30, 2024. The decrease is driven by timing differences in the collection of accounts receivable and payments made and higher inventory purchases, partly offset by increase in net income, net of non-cash adjustments.

------

**Table of Contents**

***Investing Activities***

During the six months ended June 30, 2025, cash used in investing activities was $1.5 million as compared to $0.4 million for the six months ended June 30, 2024. The increase was primarily due to capital expenditures related to the new New York, London and Singapore offices.

***Financing Activities***

During the six months ended June 30, 2025 compared to the six months ended June 30, 2024, net cash used by financing activities increased by $0.5 million, primarily driven by higher volume of share repurchases in the six months ended June 30, 2025 compared to the prior year period. See Note 10, *Stockholders' Equity,* in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, for further discussion on share repurchases.

**Debt**

We had an immaterial amount of debt outstanding as of June 30, 2025 and December 31, 2024, which was related to vehicle loans.

***Revolving Credit Facility***

In May 2020, the Company entered into the 2020 Credit Facility, which currently provides for committed borrowings of $60 million. On February 14, 2025, the 2020 Credit Facility was amended, extending the maturity five years to February 13, 2030.

Starting in December 2022, borrowings on the 2020 Credit Facility bear interest at rates based on either: 1) a fluctuating rate per annum determined to be the sum of Daily Simple SOFR plus the Spread; or 2) a fixed rate per annum determined to be the sum of the Term SOFR plus the Spread. The Spread ranges from 1.00% to 1.75%, which is based on the Company's leverage ratio (as defined in the credit agreement) for the immediately preceding fiscal quarter as defined in the credit agreement. In addition, the Company was subject to unused commitment fees ranging from 0.10% and 0.20% on the unused amount of the line of credit in the year ended December 31, 2024, with the rate based on the Company's leverage ratio (as defined in the credit agreement). As of February 14, 2025, the unused commitment fees range from 0.13% and 0.23% on the unused amount of the line of credit, with the rate being based on the Company's leverage ratio (as defined in the credit agreement).

The outstanding balance on the Revolving Facility was zero as of June 30, 2025 and December 31, 2024, respectively. As of June 30, 2025, we were compliant with all financial covenants.

***Vehicle Loans***

We periodically enter into vehicle loans. Interest rates on these vehicle loans range from 4.56% to 5.68%. The outstanding balance on the vehicle loans as of June 30, 2025 was less than $0.1 million.

For additional information, see Note 6, *Debt*, in our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

**Contractual Obligations and Commitments**

There have been no material changes to our contractual obligations from those described in the Form 10-K.

**Critical Accounting Policies and Significant Judgments and Estimates** 

Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate

------

**Table of Contents**

our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Our critical accounting policies are described under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates" in the Form 10-K and the notes to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. During the six months ended June 30, 2025, there were no material changes to our critical accounting policies from those discussed in the Form 10-K.

**Recent Accounting Pronouncements**

A description of recently adopted and issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2, *Summary of Significant Accounting Policies*, to our condensed consolidated financial statements, included in this Quarterly Report on Form 10-Q.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.** 

***Interest Rate Risk***

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities.

As of June 30, 2025 and December 31, 2024, the outstanding amounts related to our 2020 Credit Facility incur interest fees at variable interest rates and are affected by changes in the general level of market interest rates. However, there was no outstanding balance on the 2020 Credit Facility as of June 30, 2025 and December 31, 2024.

***Foreign Currency Exchange Risk***

We transact business globally in multiple currencies and hence have foreign currency risks related to our net sales, cost of goods sold and operating expenses. We use derivative financial instruments to reduce our net exposure to foreign currency fluctuations. Our objective in managing exposure to foreign currency fluctuations is to reduce the volatility caused by foreign exchange rate changes on the earnings, cash flows and financial position of our international operations. We generally target to hedge a majority of our forecasted yearly foreign currency exchange exposure through a 24-month rolling layered approach and leave a portion of our currency forecast floating at spot rate. Our currency forecast and hedge positions are reviewed quarterly. The gains and losses on the forward contracts associated with our balance sheet positions are recorded in ''Other income (expense), net" in the condensed consolidated statements of operations appearing elsewhere in this Quarterly Report on Form 10-Q.

The total notional values of our forward exchange contracts were $89.2 million and $107.4 million as of June 30, 2025 and December 31, 2024, respectively. The derivatives on the forward exchange contracts resulted in an unrealized gain of $3.9 million for the six months ended June 30, 2025, and we estimate that a 10% strengthening or weakening of the U.S. dollar would have resulted in an approximately $1.2 million gain or loss.

A portion of our cash and cash equivalents are denominated in foreign currencies. As of June 30, 2025, a 1% change in the value of the U.S. dollar compared to foreign currencies would have caused our cash and cash equivalents to decrease or increase by $0.1 million.

***Tariff and Inflation Risks***

Inflation generally affects us by increasing our cost of transportation, labor and manufacturing costs. In recent years, we have seen fluctuating transportation costs caused by global supply chain disruptions or geopolitical instability and general inflation effects, which may cause pressure on our costs and margins. More specifically, we source a large amount of our finished goods from international countries, which exposes us to international supply chain inflation, particularly ocean freight, and to changes in the strength of the U.S. dollar. In the six months ended June 30, 2025, general inflationary pressures continue to increase the other elements of our cost of goods and operating expenses. During the first quarter of 2025, various tariffs were announced on imports into the U.S. On April 2, 2025, the U.S. announced a new universal baseline tariff of 10%, plus significant additional country-specific tariffs for select trading partners, on all U.S. imports. Some of these tariff announcements have since been followed by announcements of limited exemptions and temporary pauses. The actual future tariff environment is quite uncertain.. The imposition of the baseline 10% tariff will increase our

------

**Table of Contents**

costs of goods sold. The uncertainty of future tariffs could also cause disturbances in ocean shipping capacity that could effect our ability to secure ocean freight containers for our products, and create inflationary effects on our costs, in addition to the direct impact of tariffs.

***Credit Risk***

We are exposed to concentration of credit risk from our major customers. In the six months ended June 30, 2025, sales to two customers represented approximately 45% of our consolidated net sales. We have not experienced credit issues with these customers. We maintain provisions for potential credit losses and evaluate the solvency of our customers on an ongoing basis to determine if additional allowances for doubtful accounts and customer credits need to be recorded. Significant economic disruptions or a slowdown in the economy could result in significant additional charges.

**Item 4. Controls and Procedures.** 

**Limitations on effectiveness of controls and procedures** 

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

**Evaluation of disclosure controls and procedures** 

Our management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that, as of June 30, 2025, our disclosure controls and procedures were effective at the reasonable assurance level.

**Changes in Internal Control over Financial Reporting** 

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**Table of Contents**

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.** 

From time to time, we may be involved in various claims and legal proceedings related to claims arising out of our operations. We are not currently a party to any material legal proceedings, including any such proceedings that are pending or threatened, of which we are aware.

**Item 1A. Risk Factors.** 

Please refer to Part I, Item 1A. "Risk Factors" of our Form 10-K for the fiscal year ended December 31, 2024 for a description of certain significant risks and uncertainties to which our business, financial condition and results of operations are subject. There have been no material changes to these risk factors as of June 30, 2025.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.** 

The Company did not sell any equity securities during the three months ended June 30, 2025 that were not registered under the Securities Act.

The following table provides information regarding repurchases of our Common Stock during the three months ended June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs <sup>(1)</sup> | Approximate Dollar Value of Shares That May be Purchased Under the Plans or Programs |
|  |  |  |  | (In millions) |
| April 1, 2025 - April 30, 2025 | 284728 | $30.04 | 867947 | $42.1 |
| May 1, 2025 - May 31, 2025 |  | $— |  | $— |
| June 1, 2025 - June 30, 2025 |  | $— |  | $— |

---

(1) On October 30, 2023, the Company's Board of Directors approved a share repurchase program ("Repurchase &nbsp;&nbsp;&nbsp;&nbsp;Program") authorizing the Company to repurchase up to $40.0 million of Common Stock, which was increased to a total of $65.0 million on April 28, 2025. Shares of Common Stock may be repurchased under the Repurchase Program from time to time through open market purchases, block trades, private transactions or accelerated or other structured share repurchase programs. To the extent not retired, shares of Common Stock repurchased under the Repurchase Program will be placed in the Company's treasury shares. The extent to which the Company repurchases shares of Common Stock and the timing of such repurchases will depend upon a variety of factors, including market conditions, regulatory requirements and other corporate considerations, as determined by the Company. The Repurchase Program has no time limits, and may be suspended or discontinued at any time. During the three months ended June 30, 2025, the Company repurchased 284,728 shares at a cost of $8.6 million under the Repurchase Program.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

On May 8, 2025, Verlinvest Beverages SA, a significant stockholder of the Company, completed a block sale of 3,766,762 shares of the Company's common stock at a price of $34.25 per share in a private transaction facilitated by Bank

------

**Table of Contents**

of America Securities, Inc. The transaction was executed pursuant to Rule 144 under the Securities Act of 1933, as amended.

Following the transaction, Verlinvest Beverages SA beneficially owns approximately 12.5% of the Company's outstanding common stock, down from 19.1% prior to the transaction.

The transaction does not affect the Company's capital structure or operations. This sale was undertaken as part of Verlinvest Beverages SA's ongoing portfolio management strategy and does not reflect any disagreement with the Company's management or operations.

*Rule 10b5-1 Trading Plans*

In accordance with the disclosure requirements set forth in Item 408(a) of Regulation S-K, the following table discloses any officer (as defined in Rule 16a-1(f) under the Exchange Act), director, or entity controlled by such officer or director who adopted or terminated a contract, instruction, or written plan for the sale of securities of the Company intended to satisfy the affirmative defense of Rule 10b5-1(c) during the quarterly period ended June 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Title** | **Action Taken** | **Date of Action** | **Duration of Trading Arrangement** | **Aggregate Number of Securities to be Sold** |
| Corey Baker | Chief Financial Officer | Adoption | May 12, 2025 | August 11, 2025 to March 31, 2026 | Up to 10,000 shares of Common Stock, subject to a daily maximum of 1,000 shares |
| The Michael Kirban 2012 Trust | A trust controlled by Michael Kirban (Co-Founder, Executive Chairman and Chairman of the Board) | Adoption | June 5, 2025 | September 4, 2025 to September 30, 2026 | Up to 150,000 shares of Common Stock, subject to a daily maximum of 30,000 shares |
| Ira Liran | Director | Adoption | May 7, 2025 | August 8, 2025 to August 10, 2026 | Up to 180,000 shares of Common Stock  |
| The Ira Liran 2012 Family Trust | A trust controlled by Ira Liran | Adoption | May 7, 2025 | August 8, 2025 to August 10, 2026 | Up to 270,000 shares of Common Stock |
| Charles Van Es | Chief Sales Officer | Adoption | June 13, 2025 | September 12, 2025 to March 15, 2026 | Up to 60,000 shares of Common Stock |

---

Other than as disclosed above, no other officer, director or entity controlled by such officer or director adopted, modified or terminated a contract, instruction or written plan for the purchase or sale of securities of the Company intended to satisfy the affirmative defense of Rule 10b5-1(c) or a non-Rule 10b5-1 trading arrangement.

------

**Table of Contents**

**Item 6. Exhibits.**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Exhibit<br>Number | Exhibit Description | Incorporated by Reference | Incorporated by Reference | Incorporated by Reference | Incorporated by Reference | Filed /<br>Furnished<br>Herewith |
| Exhibit<br>Number | Exhibit Description | Form | File No. | Exhibit | Filing Date | Filed /<br>Furnished<br>Herewith |
| 3.1 | <u>[Second Amended and Restated Certificate of Incorporation.](https://www.sec.gov/Archives/edgar/data/0001482981/000119312521306737/d222890dex31.htm)</u> | 8-K | 001-40950 | 3.1 | 10/25/21 |  |
| 3.2 | <u>[Amended and Restated Bylaws.](https://www.sec.gov/Archives/edgar/data/0001482981/000119312521306737/d222890dex32.htm)</u> | 8-K | 001-40950 | 3.2 | 10/25/21 |  |
| 4.1 | <u>[Specimen Common Stock Certificate of The Vita Coco Company, Inc.](https://www.sec.gov/Archives/edgar/data/0001482981/000119312521284306/d197386dex41.htm)</u> | S-1 | 333-259825 | 4.1 | 9/27/21 |  |
| 4.2+ | <u>[Registration Rights Agreement, by and among The Vita Coco Company, Inc. and certain security holders of The Vita Coco Company, Inc., dated as of October 20, 2021.](https://www.sec.gov/Archives/edgar/data/0001482981/000119312521306737/d222890dex101.htm)</u> | 8-K | 001-40950 | 10.1 | 10/25/21 |  |
| 4.3+ | <u>[Investor Rights Agreement, among The Vita Coco Company, Inc., Verlinvest Beverages SA, Michael Kirban and Ira Liran, dated as of October 20, 2021.](https://www.sec.gov/Archives/edgar/data/0001482981/000119312521306737/d222890dex102.htm)</u> | 8-K | 001-40950 | 10.2 | 10/25/21 |  |
| 4.4 | <u>[Form of Indenture](https://www.sec.gov/Archives/edgar/data/1482981/000119312523132638/d497597dex44.htm)</u> | S-3 | 333-271583 | 4.4 | 5/2/23 |  |
| 10.1+X | <u>[Third Amendment to the Manufacturing and Purchasing Agreement, by and between Century Pacific Agricultural Ventures, Inc. and All Marke](coco20250630-10qexx102.htm)[t Singapore](coco20250630-10qexx102.htm)[Pte. Ltd, dated as of June 12, 2025.](coco20250630-10qexx102.htm)</u> |  |  |  |  | \* |
| 31.1 | <u>[Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a).](coco20250630-exx311martinr.htm#if0a2fdc976da4e408f1d46e37e825b79_1)</u> |  |  |  |  | \* |
| 31.2 | <u>[Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a).](coco20250630-exx312coreyba.htm)</u> |  |  |  |  | \* |
| 32.1 | <u>[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.](coco20250630-10qexx321ceo.htm#ibda42cf9ceb04b44bd65f088e0c93f49_1)</u> |  |  |  |  | \*\* |
| 32.2 | <u>[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.](coco20250630-10qexx322cfo.htm#i262e3d7c17ed4f5082bba98bbe2aa730_1)</u> |  |  |  |  | \*\* |
| 101.INS | Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  |  |  |  | \* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | \* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  | \* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  | \* |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  | \* |

---

------

**Table of Contents**

---

| | | |
|:---|:---|:---|
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | \* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |

---

_______________________

\* Filed herewith.

\*\* Furnished herewith.

+ Certain portions of this exhibit (indicated by "####") have been redacted pursuant to Regulation S-K, Item 601(a)(6).

X Certain portions of this exhibit (indicated by "[\*\*\*]") have been redacted pursuant to Regulations S-K, Item 601(b)(10)(iv).

------

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | THE VITA COCO COMPANY, INC. | THE VITA COCO COMPANY, INC. |
| Date: July 30, 2025 | By: | /s/ Martin Roper |
|  |  | **Martin Roper** |
|  |  | **Chief Executive Officer and Director** |
|  |  | *(Principal Executive Officer)* |
| Date: July 30, 2025 | By: | /s/ Corey Baker |
|  |  | **Corey Baker** |
|  |  | **Chief Financial Officer** |
|  |  | *(Principal Financial Officer)* |

---

## Exhibit 10.2

**Exhibit 10.1**

**3**<sup>rd</sup> **AMENDMENT TO THE**

**MANUFACTURING AND PURCHASING AGREEMENT**

**(Dated September 19, 2012)**

KNOW ALL MEN BY THESE PRESENTS:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This 3<sup>rd</sup> Amendment to the Manufacturing and Purchasing Agreement (the "*3rd Amendment*") is made and entered into this 12th day of June 2025 by and between:

**CENTURY PACIFIC AGRICULTURAL VENTURES, INC.**, a corporation duly organized and existing under the laws of the Republic of the Philippines, with principal office address at Centerpoint Building, Julia Vargas Avenue corner Garnet Road, Ortigas Center, Pasig City, Philippines 1605 ("**Manufacturer**");

- and -

**ALL MARKET SINGAPORE PTE. LTD.**, a corporation duly organized and existing under the laws of Singapore, with principal office address at #02-03/04 The Galen, 61 Science Park Road, Singapore 117525 ("**Company**");

(Individually, a "Party" and collectively, the "Parties").

**RECITALS**

**WHEREAS**, the Parties entered into a *Manufacturing and Purchasing Agreement* dated 19 September 2012, as supplemented by the *Supplemental Agreement* dated 05 November 2014, amended through the *Amendment to Manufacturing and Purchasing Agreement* dated November 30, 2015 ("*1st Amendment*") and *Amendment to Manufacturing and Purchasing Agreement* dated November 20, 2020 ("*2nd Amendment*") (collectively, the "*Original Agreement*"), pursuant to which Company engaged the services of Manufacturer to manufacture and package certain Products according to Company's Specifications;

**WHEREAS**, the Parties intend to enter into this long-term Manufacturing and Purchasing Agreement to ensure a consistent and sustainable supply of the Company's Products, manufactured at the required quality, throughout the entire Term in support of the Company's growth;

**WHEREAS**, the Parties agree to extend the term of the *Original Agreement* for another period of 5 years, from 01 January 2026 to 31 December 2030;

**WHEREAS**, effective 01 January 2026, the Parties agree to amend the price, volume , and minimum volume as reflected on **Schedules 1** to **3** hereof, and other relevant terms as specified herein;

------

**NOW THEREFORE**, for and in consideration of the foregoing premises, the Parties agree as follows:

Section 1.***Definitions***. – Certain capitalized words and expressions under this Agreement shall have the meanings set forth under the *Original Agreement*, except as otherwise defined herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Effective Date*** – The terms and revisions reflected in this *3*<sup>rd</sup> *Amendment* shall take effect on 01 January 2026, unless otherwise specifically stated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Term of the Agreement*** – The term of the *Original Agreement* is hereby extended for another period of 5 years, from 01 January 2026 to 31 December 2030.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Products and Price*** – The Products and corresponding Price subject of the *Original Agreement* are hereby amended as specified in **Schedule 1** hereof. Further, the Parties agree that the price may be adjusted based on the mechanism specified herein and in said **Schedule 1**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Annual Volume*** *–* For each calendar year, the Parties shall endeavor to order and produce Products based on the volumes specified in **Schedule 2** hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Minimum Volume*** *–* Manufacturer shall produce for Company and Company commits to order from Manufacturer the volume specified in **Schedule 3** hereof. The Parties shall adhere to the penalty indicated therein for non-compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Interpretative Provisions.*** – For purposes of incorporating the agreements of the Parties hereunder, the *Original Agreement* shall be deemed amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)**Schedules 1, 2,** and **3** of the *2nd Amendment* shall be replaced by **Schedules 1, 2,** and **3** hereof, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Except as specifically amended hereby, the provisions of the *Original Agreement* shall continue in full force and effect and be binding on each Party thereto in accordance with their terms. From and after the execution of this Agreement, all references in the Original Agreement to the "Agreement", "this Agreement", "hereof", "hereunder", "herein" and words of similar import shall be deemed to be references to the *Original Agreement* as amended by this *3*<sup>rd</sup> *Amendment*, and the *Original Agreement* shall be read and construed with this *3*<sup>rd</sup> *Amendment* as one integrated document incorporating the provisions amended hereby.

Section 1.***New Section 2.7* –** A new section 2.7 is hereby added to the *Original Agreement*.

"Section 2.7 **ESG (Environmental, Social and Governance) Responsibilities** - The Parties acknowledge that Company has certain commitments to expand its Environmental, Social, and Governance ("ESG") framework, including opportunities to reduce Company's overall environmental impact. Manufacturer hereby agrees to promote Company's sustainability objectives in connection with its ESG framework. Manufacturer further agrees to

------

use commercially reasonable efforts to adopt policies and measures on Company's guidance targets:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)[\*\*\*];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)[\*\*\*];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)[\*\*\*];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)[\*\*\*];

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)[\*\*\*]; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)[\*\*\*].

[\*\*\*].

During the Term, Manufacturer also agrees to use its commercially reasonable efforts to improve its energy reduction in the manufacturing, processing, and packaging of the Products on a yearly basis. Upon request, Manufacturer shall provide Company with accurate reports on its energy reduction."

Section 1.***Revised Section 14.3*** – Section 14.3 of the *Original Agreement* is hereby amended to include the following new subsections (xii) – (xiv):

Manufacturer represents, warrants, and covenants to Company that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) Manufacturer agrees to undergo a Sedex Members Ethical Trade Audit ("SMETA") on an annual basis. Within thirty (30) days following completion of each SMETA, Manufacturer shall provide a certification to AMS confirming that SMETA has been conducted. Additionally, Manufacturer shall furnish to AMS a complete copy of the corresponding SMETA report. If Manufacturer fails to undergo SMETA on an annual basis, Manufacturer shall promptly notify Company of such default and the Parties will work in good faith to resolve such default prior to the completion of that year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) Manufacturer agrees to collect, maintain, and provide applicable and accurate production data to Company's Laboratory Information Management System ("LIMS") in a timely manner as agreed to by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) Manufacturer agrees to collect, maintain, and provide applicable and accurate data to Company's Environmental Management System ("EMS") in a timely manner as agreed to by the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Representations and Warranties.*** – Each Party represents, warrants and covenants to the other Party that: (i) it has full power, authority and legal right to make and perform this *3*<sup>rd</sup> *Amendment*; (ii) all necessary corporate and other legal approvals or consents and other legal action required for the making and performance of this *3*<sup>rd</sup> *Amendment* and the transactions contemplated hereby have been obtained or made and are and will continue to be in effect; and (iii) this *3*<sup>rd</sup> *Amendment* constitutes the legal, valid and binding obligation of the Party, enforceable in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Counterparts.*** – This *3*<sup>rd</sup> *Amendment* may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so

------

executed and delivered shall be an original, but all of which shall together constitute one and the same document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.***Governing Law***. – The *Original Agreement*, *1*<sup>st</sup> Amendment, *2*<sup>nd</sup> *Amendment*, and *3*<sup>rd</sup> *Amendment* shall be governed by and construed in accordance with the laws of the Republic of the Philippines.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**IN WITNESS WHEREOF**, the parties hereto have set their hands on the date and at the place first above-written.

*- signature page(s) to follow -* 

------

**MANUFACTURER: CENTURY PACIFIC AGRICULTURAL VENTURES, INC.**

By: /s/ Christopher Paulus T. Po

**Christopher Paulus T. Po**

*President and Chief Executive Officer*

**COMPANY: ALL MARKET SINGAPORE PTE. LTD.**

By: /s/ Jonathan Burth

**Jonathan Burth**

*Chief Operating Officer*

------

**SCHEDULE 1**

**<u>PRODUCTS AND PRICES PURE COCONUT PRODUCTS</u>**

*<u>As stated in the 1</u>*<sup>st</sup>*<u>Amendment</u>*

[\*\*\*]

*<u>As stated in the 2</u>*<sup>nd</sup>*<u>Amendment</u>*

[\*\*\*]

***3***<sup>rd</sup> ***Amendment***

[\*\*\*]

------

**SCHEDULE 2**

**<u>ANNUAL VOLUME GUIDE</u>**

*<u>As stated in the 1</u>*<sup>st</sup>*<u>Amendment</u>*

[\*\*\*]

**<u>ANNUAL VOLUME GUIDE</u>**

*<u>As stated in the 2nd Amendment</u>*

[\*\*\*]

**SCHEDULE 2**

**<u>ANNUAL VOLUME GUIDE</u>**

*<u>3</u>*<sup>rd</sup>*<u>Amendment</u>*

[\*\*\*]

------

**SCHEDULE 3**

**MINIMUM ORDER VOLUME** 

*<u>3</u>*<sup>rd</sup>*<u>Amendment</u>*

[\*\*\*]

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

I, Martin Roper, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of The Vita Coco Company, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: July 30, 2025 | By: | /s/ Martin Roper |
|  |  | Martin Roper |
|  |  | Chief Executive Officer |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Corey Baker, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of The Vita Coco Company, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: July 30, 2025 | By: | /s/ Corey Baker |
|  |  | Corey Baker |
|  |  | Chief Financial Officer |
|  |  | *(Principal Financial Officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of The Vita Coco Company, Inc. (the "Company") for the quarter ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Martin Roper, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: July 30, 2025 | By: /s/ Martin Roper |
|  | Martin Roper |
|  | Chief Executive Officer |
|  | *(Principal Executive Officer)* |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of The Vita Coco Company, Inc. (the "Company") for the quarter ended June 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Corey Baker, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: July 30, 2025 | By: /s/ Corey Baker |
|  | Corey Baker |
|  | Chief Financial Officer |
|  | *(Principal Financial Officer)* |

---

<br>